Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Darifenacin	Clinically Important Improvement in UI	Steers, 2005[43] 11.25	160/268	60/127	1.3 (1.0;1.6)	56.93	0.125 (0.02;0.23)	32.51
Darifenacin	Clinically Important Improvement in UI	Hill, 2006[42] 7.5	28/108	15/109	1.9 (1.1;3.3)	7.67	0.122 (0.02;0.23)	32.43
Darifenacin	Clinically Important Improvement in UI	Chapple, 2007[255] 7.5	122/266	47/133	1.3 (1.0;1.7)	35.39	0.105 (0.00;0.21)	35.06
Darifenacin	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.1;1.5)	100	0.117 (0.06;0.18)	100.0
Darifenacin	Clinically Important Improvement in UI	P value/I squared			0.422	0	0.961	0
Fesoterodine	Continence	Kaplan, 2010[318] 6	609/963	258/480	1.18 (1.07; 1.30)	54.44	0.095 (0.04; 0.15)	52.89
Fesoterodine	Continence	NCT00444925[56] 6	396/685	138/337	1.41 (1.22; 1.63)	45.56	0.169 (0.10; 0.23)	47.11
Fesoterodine	Continence	Pooled RR (IV)			1.28 (1.07; 1.53)	100	0.130 (0.06; 0.20)	100
Fesoterodine	Continence	P value/I squared			0.038	0.767	0.085	0.663
Fesoterodine	Clinically Important Improvement in UI	Dmochowski, 2010[469] 6	182/438	137/445	1.35 (1.13; 1.61)	48.54	0.108 (0.05; 0.17)	49.96
Fesoterodine	Clinically Important Improvement in UI	Herschorn, 2010[470] 6	293/679	113/334	1.28 (1.07; 1.52)	51.46	0.093 (0.03; 0.16)	50.04
Fesoterodine	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.2;1.5)	100	0.10 (0.06;0.15)	100
Fesoterodine	Clinically Important Improvement in UI	P value/I squared			0.655	0	0.75	0
Oxybutynin		Moore, 1990[351] 3	5/28	0/25	9.86 (0.57; 169.86)	0.76	0.179 (0.03; 0.33)	10.58
Oxybutynin	Continence	Staskin, 2009[31] 10	108/389	69/400	1.61 (1.23; 2.10)	86.2	0.105 (0.05; 0.16)	73.07
Oxybutynin	Continence	Lehtoranta, 2002[334] 15	4/9	2/9	2.00 (0.48; 8.31)	3.05	0.222 (-0.20; 0.65)	1.37
Oxybutynin	Continence	Burgio, 1998[238] 11.5	15/67	8/65	1.82 (0.83; 4.00)	9.98	0.101 (-0.03; 0.23)	14.99
Oxybutynin	Continence	Pooled RR (IV)			1.7 (1.3;2.1)	100	0.11 (0.06;0.16)	100
Oxybutynin	Continence	P value/I squared			0.643	0	0.783	0
Oxybutynin	Clinically Important Improvement in UI	Moore, 1990[351] 3	10/28	1/25	8.93 (1.23; 64.90)	1.1	0.317 (0.12; 0.51)	8.41

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Oxybutynin	Clinically Important Improvement in UI	Johnson, 2005[313] 4	4/46	1/38	3.30 (0.39; 28.33)	0.94	0.061 (-0.04; 0.16)	15.35
Oxybutynin	Clinically Important Improvement in UI	Szonyi, 1995[382] 5	22/28	16/29	1.42 (0.97; 2.08)	15.18	0.234 (0.00; 0.47)	6.49
Oxybutynin	Clinically Important Improvement in UI	Wang, 2006[413] 7.5	2/23	0/21	4.58 (0.23; 90.30)	0.5	0.087 (-0.05; 0.22)	11.98
Oxybutynin	Clinically Important Improvement in UI	Homma, 2003[307] 9	129/244	31/122	2.10 (1.51; 2.91)	17.44	0.277 (0.18; 0.38)	15.09
Oxybutynin	Clinically Important Improvement in UI	Madersbacher, 1999[343] 10	116/145	43/72	1.34 (1.09; 1.65)	23.22	0.203 (0.07; 0.33)	12.48
Oxybutynin	Clinically Important Improvement in UI	Burgio, 1998[238] 11.5	37/67	20/65	1.80 (1.18; 2.74)	13.6	0.245 (0.08; 0.41)	10.14
Oxybutynin	Clinically Important Improvement in UI	Thuroff, 1991[386] 15	26/63	15/52	1.43 (0.85; 2.40)	17.32	0.124 (-0.05; 0.30)	10.51
Oxybutynin	Clinically Important Improvement in UI	Abrams, 1998[219] 15	58/118	27/57	1.04 (0.75; 1.44)	10.7	0.018 (-0.14; 0.18)	9.55
Oxybutynin	Clinically Important Improvement in UI	Pooled RR (IV)			1.5 (1.2;1.9)	100	0.17 (0.10;0.24)	100
Oxybutynin	Clinically Important Improvement in UI	P value/I squared			0.064	0.459	0.02	0.559
Solifenacin	Clinically Important Improvement in UI	Toglia, 2009[321] 7.5	260/372	206/367	1.25 (1.11; 1.39)	52.27	0.138 (0.07; 0.21)	49.62
Solifenacin	Clinically Important Improvement in UI	Vardy, 2009[392] 5 to 10	196/386	109/382	1.78 (1.48; 2.15)	47.73	0.222 (0.16; 0.29)	50.38
Solifenacin	Clinically Important Improvement in UI	Pooled RR (IV)			1.48 (1.04; 2.09)	100	0.180 (0.10; 0.26)	100
Solifenacin	Clinically Important Improvement in UI	P value/I squared			0.001	0.903	0.085	0.664
Solifenacin	Continence	Cardozo, 2006[412] 5	160/314	266/781	1.50 (1.29; 1.73)	23.09	0.169 (0.10; 0.23)	14.08
Solifenacin	Continence	Staskin, 2006[37] 5	49/159	122/430	1.53 (1.36; 1.72)	34.95	0.180 (0.13; 0.23)	15.75
Solifenacin	Continence	Karram, 2009[320] 7.5	133/372	93/367	1.09 (0.82; 1.43)	6.4	0.024 (-0.06; 0.11)	12.11
Solifenacin	Continence	Cardozo, 2006[412] 10	405/778	266/781	1.44 (1.19; 1.73)	14.08	0.123 (0.06; 0.19)	14.32

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Solifenacin	Continence	Staskin, 2006[37] 10	184/452	122/430	1.41 (1.13; 1.76)	9.96	0.104 (0.04; 0.17)	13.92
Solifenacin	Continence	Chu, 2009[264] 10	119/340	80/332	1.32 (0.88; 1.99)	2.95	0.030 (-0.01; 0.07)	16.16
Solifenacin	Continence	Vardy, 2009[392] 5 to 10	48/386	36/382	1.45 (1.14; 1.85)	8.56	0.109 (0.04; 0.18)	13.66
Solifenacin	Continence	Pooled RR (IV)			1.45 (1.35; 1.56)	100	0.107 (0.06; 0.16)	100
Solifenacin	Continence	P value/I squared			0.496	0	0	0.786
Tolterodine	Continence	Rogers, 2008[365] 4	115/202	89/211	1.35 (1.11; 1.65)	22.57	0.148 (0.05; 0.24)	17.05
Tolterodine	Continence	Malone-Lee, 2009[345] 4	41/165	26/142	1.36 (0.88; 2.10)	6.99	0.065 (-0.03; 0.16)	18.14
Tolterodine	Continence	Kaplan, 2010[318] 4	566/974	258/480	1.08 (0.98; 1.19)	39.93	0.044 (-0.01; 0.10)	35.49
Tolterodine	Continence	NCT00444925[56] 6	358/690	138/337	1.27 (1.09; 1.47)	30.52	0.109 (0.05; 0.17)	29.32
Tolterodine	Continence	Pooled RR (IV)			1.21 (1.07; 1.37)	100	0.085 (0.04; 0.13)	100
Tolterodine	Continence	P value/I squared			0.11	0.502	0.209	0.34
Tolterodine	Clinically Important Improvement in UI	Kelleher, 20020[323] 4	294/507	218/508	1.35 (1.19; 1.53)	18.63	0.151 (0.09; 0.21)	14.81
Tolterodine	Clinically Important Improvement in UI	Herschorn, 2008[301,471] 4	156/410	64/207	1.23 (0.97; 1.56)	11.93	0.071 (-0.01; 0.15)	13.12
Tolterodine	Clinically Important Improvement in UI	Sand, 2009[370] 4	140/227	167/430	1.59 (1.36; 1.86)	16.59	0.228 (0.15; 0.31)	13.15
Tolterodine	Clinically Important Improvement in UI	Rogers, 2009[364] 4	79/202	58/211	1.42 (1.08; 1.88)	10.09	0.116 (0.03; 0.21)	12.01
Tolterodine	Clinically Important Improvement in UI	Herschorn, 2010[470] 4	256/684	113/334	1.11 (0.93; 1.32)	15.24	0.036 (-0.03; 0.10)	14.67
Tolterodine	Clinically Important Improvement in UI	Kaplan, 2010318 4	654/974	287/480	1.12 (1.03; 1.22)	20.99	0.074 (0.02; 0.13)	15.55
Tolterodine	Clinically Important Improvement in UI	NCT00444925[56] 6	79/690	32/337	1.21 (0.82; 1.78)	6.52	0.020 (-0.02; 0.06)	16.7
Tolterodine	Clinically Important Improvement in UI	Pooled RR (IV)			1.3 (1.1;1.4)	100	0.10 (0.04;0.15)	100
Tolterodine	Clinically Important Improvement in UI	P value/I squared			0.004	0.685	0	0.804

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk and absolute risk differences pooled with random effects models, weighs using inverse variance method

Active Drug	Outcome	Reference Dose	Events/ randomized with drug	Events/ randomized with placebo	Relative risk (95% CI)	Weight, inverse variance	Absolute risk difference (95% CI)	Weight, Inverse variance
Trospium	Continence	Zinner, 2004[35] 40	55/262	29/261	1.89 (1.25; 2.86)	12.28	0.099 (0.04; 0.16)	23.9
Trospium	Continence	Staskin, 2007[45] 60	61/298	34/303	1.82 (1.24; 2.69)	14.12	0.092 (0.04; 0.15)	27.62
Trospium	Continence	Dmochowski, 2008[272] 60	95/280	58/284	1.66 (1.25; 2.20)	26.74	0.135 (0.06; 0.21)	17.61
Trospium	Continence	Sand, 2009[371] 60	163/484	103/505	1.65 (1.34; 2.04)	46.86	0.133 (0.08; 0.19)	30.87
Trospium	Continence	Pooled RR (IV)			1.71 (1.47; 1.97)	100	0.114 (0.08; 0.14)	100
Trospium	Continence	P value/I squared			0.925	0	0.675	0
Trospium	Clinically Important Improvement in UI	Staskin, 2004[378] 20	5/327	8/326	0.62 (0.21; 1.89)	21.8	-0.009 (-0.03; 0.01)	52.53
Trospium	Clinically Important Improvement in UI	Zinner, 2004[35] 40	186/262	141/261	1.31 (1.15; 1.51)	78.2	0.170 (0.09; 0.25)	47.47
Trospium	Clinically Important Improvement in UI	Pooled RR (IV)			1.12 (0.61; 2.04)	100	0.076 (-0.10; 0.25)	100
Trospium	Clinically Important Improvement in UI	P value/I squared			0.19	0.419	0	0.942

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 7.5mg	Adverse effects	Hill, 2006[42]	62/108	54/109	0.19 (0.06 to 0.33)	17.46	0.19 (0.06 to 0.30)	17.46
Darifenacin 7.5mg	Adverse effects	Chapple, 2007[255]	99/266	24/133	0.08 (-0.05 to 0.21)	17.51	0.06 (-0.04 to 0.19)	17.51
Darifenacin 15mg	Adverse effects	Hill, 2006[42]	73/107	54/109	0.33 (0.20 to 0.46)	17.82	0.31 (0.19 to 0.40)	17.82
Darifenacin 15mg	Adverse effects	Zinner, 2006[407]	136/214	110/225	0.15 (0.06 to 0.24)	24.68	0.15 (0.05 to 0.23)	24.68

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 30mg	Adverse effects	Hill, 2006[42]	92/115	54/109	0.22 (0.11 to 0.32)	22.54	0.21 (0.11 to 0.30)	22.54
Darifenacin	Adverse effects	Pooled	462/810	296/685	0.19 (0.12 to 0.27)	100	0.19 (0.12 to 0.26)	100
Darifenacin	Adverse effects	Heterogeneity			p value 0.097	49.10%	I-squared	49.10%
Darifenacin 15mg	Nausea	Lipton, 2005[337]	1/65	1/69	0.00 (-0.17 to 0.17)	23.38	0.00 (-0.01 to 0.07)	23.38
Darifenacin 15mg	Nausea	Zinner, 2006[407]	3/214	2/225	0.03 (-0.07 to 0.12)	76.62	0.01 (-0.01 to 0.03)	76.62
Darifenacin	Nausea	Pooled	4/279	3/294	0.02 (-0.06 to 0.11)	100	0.00 (-0.01 to 0.03)	100
Darifenacin	Nausea	Heterogeneity			p value 0.799	0.00%	I-squared	0.00%
Darifenacin 15mg	Serious adverse effects	Hill, 2006[42]	2/107	2/109	0.00 (-0.13 to 0.14)	32.99	0.00 (-0.02 to 0.05)	32.99
Darifenacin 15mg	Serious adverse effects	Zinner, 2006[407]	2/214	5/225	-0.05 (-0.15 to 0.04)	67.01	-0.01 (-0.02 to 0.01)	67.01
Darifenacin	Serious adverse effects	Pooled	4/321	7/334	-0.04 (-0.11 to 0.04)	100	-0.01 (-0.02 to 0.01)	100
Darifenacin	Serious adverse effects	Heterogeneity			p value 0.515	0.00%	I-squared	0.00%
Darifenacin 15mg	Urinary tract infection	Hill, 2006[42]	3/107	2/109	0.03 (-0.10 to 0.17)	32.99	0.01 (-0.02 to 0.07)	32.99
Darifenacin 15mg	Urinary tract infection	Zinner, 2006[407]	6/214	6/225	0.01 (-0.08 to 0.11)	67.01	0.00 (-0.02 to 0.04)	67.01
Darifenacin	Urinary tract infection	Pooled	9/321	8/334	0.02 (-0.06 to 0.10)	100	0.01 (-0.01 to 0.04)	100
Darifenacin	Urinary tract infection	Heterogeneity			p value 0.808	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Constipation	Hill, 2006[42]	17/108	5/109	-0.07 (-0.22 to 0.09)	11.16	-0.02 (-0.05 to 0.04)	11.16
Darifenacin 7.5mg	Constipation	Chapple, 2007[255]	41/266	11/133	0.13 (0.03 to 0.23)	13.83	0.08 (0.02 to 0.16)	13.83
Darifenacin 15mg	Constipation	Chapple, 2004[472]	2/53	11/164	0.06 (-0.11 to 0.23)	10.48	0.03 (-0.04 to 0.16)	10.48
Darifenacin 15mg	Constipation	Lipton, 2005[337]	8/65	6/69	0.19 (0.06 to 0.33)	12.22	0.14 (0.04 to 0.25)	12.22

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Constipation	Hill, 2006[42]	27/107	5/109	0.31 (0.18 to 0.44)	12.21	0.21 (0.10 to 0.33)	12.21
Darifenacin 15mg	Constipation	Zinner, 2006[407]	9/214	8/225	0.34 (0.21 to 0.47)	12.32	0.22 (0.12 to 0.34)	12.32
Darifenacin 30mg	Constipation	Chapple, 2004[472]	33/229	11/164	0.02 (-0.07 to 0.12)	14.14	0.01 (-0.03 to 0.07)	14.14
Darifenacin 30mg	Constipation	Hill, 2006[42]	32/115	5/109	0.11 (0.01 to 0.22)	13.64	0.06 (0.00 to 0.13)	13.64
Darifenacin	Constipation	Pooled	169/1157	62/1082	0.14 (0.05 to 0.23)	100	0.08 (0.02 to 0.15)	100
Darifenacin	Constipation	Heterogeneity			p value 0	76.60%	I-squared	76.60%
Darifenacin 15mg	Treatment discontinuation	Chapple, 2004[472]	4/53	12/164	0.00 (-0.15 to 0.16)	26.75	0.00 (-0.06 to 0.10)	26.75
Darifenacin 15mg	Treatment discontinuation	Zinner, 2006[407]	29/214	37/225	-0.04 (-0.13 to 0.05)	73.25	-0.03 (-0.09 to 0.04)	73.25
Darifenacin	Treatment discontinuation	Pooled	33/267	49/389	-0.03 (-0.11 to 0.05)	100	-0.02 (-0.06 to 0.04)	100
Darifenacin	Treatment discontinuation	Heterogeneity			p value 0.626	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Steers, 2005[43]	12/108	4/41	-0.11 (-0.27 to 0.04)	6.71	-0.06 (-0.09 to 0.03)	6.71
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Hill, 2006[42]	2/108	3/109	0.00 (-0.10 to 0.10)	11.72	0.00 (-0.02 to 0.04)	11.72
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	Chapple, 2007[255]	12/266	9/133	0.02 (-0.16 to 0.20)	5.34	0.01 (-0.06 to 0.13)	5.34
Darifenacin 7.5mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[41,390]	3/229	3/164	-0.12 (-0.29 to 0.05)	5.75	-0.02 (0.01 to 0.02)	5.75

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Chapple, 2004[472]	0/53	2/164	-0.03 (-0.16 to 0.10)	8.31	-0.01 (-0.01 to 0.03)	8.31
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Steers, 2005[43]	6/160	4/41	0.18 (0.05 to 0.31)	8.48	0.13 (0.03 to 0.24)	8.48
Darifenacin 15mg	Treatment discontinuation due to adverse effects	Zinner, 2006[407]	17/214	10/225	0.07 (-0.02 to 0.17)	12.59	0.03 (-0.01 to 0.09)	12.59
Darifenacin 15mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[41,390]	8/112	4/115	-0.05 (-0.15 to 0.06)	11.24	-0.02 (-0.03 to 0.02)	11.24
Darifenacin 15mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[41,390]	3/115	3/164	0.08 (-0.05 to 0.21)	8.56	0.03 (-0.01 to 0.10)	8.56
Darifenacin 30mg	Treatment discontinuation due to adverse effects	Chapple, 2004[472]	3/229	2/164	-0.02 (-0.12 to 0.08)	11.72	0.00 (-0.01 to 0.02)	11.72
Darifenacin 30mg	Treatment discontinuation due to adverse effects	Hill, 2006[42]	13/115	3/109	0.03 (-0.09 to 0.15)	9.58	0.01 (-0.02 to 0.07)	9.58
Darifenacin	Treatment discontinuation due to adverse effects	Pooled	79/1709	47/1429	0.01 (-0.04 to 0.06)	100	0.00 (-0.01 to 0.02)	100
Darifenacin	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.105	36.80%	I-squared	36.80%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin 15mg	Treatment discontinuation due to failure	Hill, 2006[42]	2/107	2/109	0.00 (-0.13 to 0.14)	17.55	0.00 (-0.02 to 0.05)	17.55
Darifenacin 15mg	Treatment discontinuation due to failure	Zinner, 2006[407]	2/214	5/225	-0.05 (-0.15 to 0.04)	35.66	-0.01 (-0.02 to 0.01)	35.66
Darifenacin 15mg	Treatment discontinuation due to failure	U.S. Food and Drug Administration[41,390]	1/112	2/115	-0.04 (-0.17 to 0.09)	18.45	-0.01 (-0.02 to 0.03)	18.45
Darifenacin 15mg	Treatment discontinuation due to failure	U.S. Food and Drug Administration[41,390]	2/269	1/129	0.00 (-0.11 to 0.10)	28.34	0.00 (-0.01 to 0.03)	28.34
Darifenacin	Treatment discontinuation due to failure	Pooled	7/702	10/578	-0.03 (-0.08 to 0.03)	100	-0.01 (-0.01 to 0.01)	100
Darifenacin	Treatment discontinuation due to failure	Heterogeneity			p value 0.871	0.00%	I-squared	0.00%
Darifenacin 7.5mg	Dry mouth	Lipton, 2005[337]	5/74	2/69	0.08 (-0.08 to 0.23)	10.64	0.03 (-0.02 to 0.12)	10.64
Darifenacin 7.5mg	Dry mouth	Hill, 2006[42]	25/108	6/109	0.15 (0.05 to 0.25)	11.74	0.09 (0.03 to 0.17)	11.74
Darifenacin 7.5mg	Dry mouth	Chapple, 2007[255]	59/266	5/133	0.09 (-0.07 to 0.26)	10.43	0.04 (-0.02 to 0.15)	10.43
Darifenacin 15mg	Dry mouth	Chapple, 2004[472]	7/53	14/164	0.14 (-0.03 to 0.31)	10.31	0.09 (-0.02 to 0.24)	10.31
Darifenacin 15mg	Dry mouth	Lipton, 2005[337]	6/65	2/69	0.27 (0.13 to 0.40)	11.11	0.15 (0.06 to 0.26)	11.11
Darifenacin 15mg	Dry mouth	Hill, 2006[42]	43/107	6/109	0.45 (0.32 to 0.58)	11.1	0.35 (0.22 to 0.48)	11.1
Darifenacin 15mg	Dry mouth	Zinner, 2006[407]	15/214	10/225	0.64 (0.51 to 0.77)	11.15	0.52 (0.39 to 0.65)	11.15
Darifenacin 30mg	Dry mouth	Chapple, 2004[472]	43/229	14/164	0.06 (-0.03 to 0.16)	11.85	0.04 (-0.02 to 0.11)	11.85
Darifenacin 30mg	Dry mouth	Hill, 2006[42]	68/115	6/109	0.30 (0.19 to 0.40)	11.67	0.20 (0.12 to 0.30)	11.67

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Darifenacin	Dry mouth	Pooled	271/1231	65/1151	0.24 (0.12 to 0.37)	100	0.16 (0.07 to 0.27)	100
Darifenacin	Dry mouth	Heterogeneity			p value 0	88.90%	I-squared	88.90%
Darifenacin 7.5mg	Dyspepsia	Lipton, 2005[337]	1/74	1/69	-0.02 (-0.13 to 0.08)	17.98	-0.01 (-0.01 to 0.02)	17.98
Darifenacin 7.5mg	Dyspepsia	Hill, 2006[42]	4/108	1/109	0.00 (-0.17 to 0.16)	10.8	0.00 (0.00 to 0.05)	10.8
Darifenacin 15mg	Dyspepsia	Lipton, 2005[337]	4/71	1/69	0.12 (-0.05 to 0.29)	10.66	0.04 (-0.01 to 0.14)	10.66
Darifenacin 15mg	Dyspepsia	Hill, 2006[42]	9/107	1/109	0.10 (-0.04 to 0.23)	13.81	0.03 (-0.01 to 0.09)	13.81
Darifenacin 15mg	Dyspepsia	Zinner, 2006[407]	9/214	2/225	0.20 (0.07 to 0.33)	13.77	0.08 (0.02 to 0.17)	13.77
Darifenacin 30mg	Dyspepsia	Chapple, 2004[472]	4/229	4/164	0.20 (0.07 to 0.33)	14.04	0.10 (0.03 to 0.20)	14.04
Darifenacin 30mg	Dyspepsia	Hill, 2006[42]	10/115	1/109	0.10 (0.00 to 0.19)	18.95	0.03 (0.00 to 0.07)	18.95
Darifenacin	Dyspepsia	Pooled	41/918	11/854	0.10 (0.03 to 0.16)	100	0.03 (0.01 to 0.06)	100
Darifenacin	Dyspepsia	Heterogeneity			p value 0.066	49.30%	I-squared	49.30%
Darifenacin 7.5mg	Headache	Lipton, 2005[337]	1/74	0/69	0.12 (-0.05 to 0.28)	12.37	0.01 (0.00 to 0.08)	12.37
Darifenacin 7.5mg	Headache	Hill, 2006[42]	7/108	2/109	0.17 (0.00 to 0.33)	12.12	0.07 (0.00 to 0.19)	12.12
Darifenacin 15mg	Headache	Lipton, 2005[337]	2/71	0/69	0.12 (-0.01 to 0.26)	18.8	0.01 (0.00 to 0.06)	18.8
Darifenacin 15mg	Headache	Hill, 2006[42]	7/107	2/109	0.12 (-0.01 to 0.26)	18.71	0.05 (0.00 to 0.13)	18.71
Darifenacin 15mg	Headache	Zinner, 2006[407]	7/214	2/225	0.07 (-0.02 to 0.17)	38	0.02 (0.00 to 0.06)	38
Darifenacin	Headache	Pooled	24/574	6/581	0.11 (0.05 to 0.17)	100	0.03 (0.01 to 0.06)	100
Darifenacin	Headache	Heterogeneity			p value 0.886	0.00%	I-squared	0.00%
Fesoterodine 4mg	Dry mouth	Chapple, 2004[261]	47/186	16/183	0.22 (0.12 to 0.32)	8.41	0.16 (0.08 to 0.25)	8.41

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 4mg	Dry mouth	Chapple, 2007[253]	59/272	20/285	0.23 (0.13 to 0.33)	8.27	0.16 (0.08 to 0.25)	8.27
Fesoterodine 4mg	Dry mouth	Nitti, 2007[353]	45/283	19/274	0.32 (0.22 to 0.42)	8.41	0.24 (0.15 to 0.33)	8.41
Fesoterodine 6mg	Dry mouth	Dmochowski, 2010[469]	113/438	34/445	0.22 (0.13 to 0.30)	9.91	0.15 (0.08 to 0.22)	9.91
Fesoterodine 6mg	Dry mouth	Herschorn, 2010[470]	189/679	20/334	0.35 (0.27 to 0.43)	10.01	0.26 (0.18 to 0.34)	10.01
Fesoterodine 6mg	Dry mouth	Kaplan, 2010[318]	270/963	24/480	0.14 (0.06 to 0.23)	9.91	0.08 (0.03 to 0.14)	9.91
Fesoterodine 8mg	Dry mouth	Chapple, 2004[261]	45/173	16/183	0.37 (0.29 to 0.46)	9.89	0.30 (0.22 to 0.38)	9.89
Fesoterodine 8mg	Dry mouth	Chapple, 2007[253]	97/288	20/285	0.25 (0.19 to 0.32)	11.39	0.18 (0.12 to 0.24)	11.39
Fesoterodine 8mg	Dry mouth	Nitti, 2007[353]	99/279	19/274	0.31 (0.24 to 0.37)	11.43	0.23 (0.17 to 0.29)	11.43
Fesoterodine 12mg	Dry mouth	Chapple, 2004[261]	63/186	16/183	0.33 (0.28 to 0.39)	12.37	0.26 (0.21 to 0.32)	12.37
Fesoterodine	Dry mouth	Pooled	1026/3747	205/2926	0.28 (0.23 to 0.32)	100	0.20 (0.16 to 0.24)	100
Fesoterodine	Dry mouth	Heterogeneity			p value 0.001	67.50%	I-squared	67.50%
Fesoterodine 6mg	Abdominal pain	NCT00444925[56]	10/685	4/337	0.09 (-0.02 to 0.19)	22.91	0.03 (0.00 to 0.07)	22.91
Fesoterodine 8mg	Abdominal pain	Chapple, 2004[261]	14/173	7/183	0.09 (-0.02 to 0.19)	23.71	0.04 (-0.01 to 0.10)	23.71
Fesoterodine 12mg	Abdominal pain	Chapple, 2004[261]	15/186	7/183	0.01 (-0.05 to 0.08)	53.38	0.00 (-0.02 to 0.04)	53.38
Fesoterodine	Abdominal pain	Pooled	39/1044	19/703	0.05 (-0.01 to 0.10)	100	0.02 (0.00 to 0.04)	100
Fesoterodine	Abdominal pain	Heterogeneity			p value 0.338	7.80%	I-squared	7.80%
Fesoterodine 6mg	Treatment discontinuation due to failure	Dmochowski, 2010[469]	5/438	16/445	-0.08 (-0.15 to -0.02)	49.92	-0.02 (-0.03 to -0.01)	49.92
Fesoterodine 6mg	Treatment discontinuation due to failure	Herschorn, 2010[470]	13/679	5/334	0.02 (-0.05 to 0.08)	50.08	0.00 (-0.01 to 0.03)	50.08

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine	Treatment discontinuation due to failure	Pooled	18/1117	21/779	-0.03 (-0.13 to 0.06)	100	-0.01 (-0.03 to 0.02)	100
Fesoterodine	Treatment discontinuation due to failure	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Fesoterodine 4mg	Dizziness	Chapple, 2004[261]	7/186	5/183	0.03 (-0.08 to 0.13)	18.47	0.01 (-0.02 to 0.06)	18.47
Fesoterodine 6mg	Dizziness	NCT00444925[56]	8/685	3/337	-0.07 (-0.18 to 0.03)	17.81	-0.01 (0.00 to 0.01)	17.81
Fesoterodine 8mg	Dizziness	Chapple, 2004[261]	2/173	5/183	-0.03 (-0.13 to 0.07)	18.47	-0.01 (-0.03 to 0.03)	18.47
Fesoterodine 12mg	Dizziness	Chapple, 2004[261]	4/186	5/183	0.01 (-0.05 to 0.08)	45.24	0.00 (-0.01 to 0.03)	45.24
Fesoterodine	Dizziness	Pooled	21/1230	19/886	-0.01 (-0.05 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Fesoterodine	Dizziness	Heterogeneity			p value 0.449	0.00%	I-squared	0.00%
Fesoterodine 4mg	Dry eye	Chapple, 2007[253]	6/272	0/285	0.15 (0.07 to 0.23)	16.19	0.02 (0.00 to 0.05)	16.19
Fesoterodine 4mg	Dry eye	Nitti, 200 [353]	2/283	0/274	0.21 (0.12 to 0.29)	16.28	0.04 (0.02 to 0.08)	16.28
Fesoterodine 6mg	Dry eye	Dmochowski, 2010[469]	13/438	8/445	0.08 (0.00 to 0.17)	16.19	0.03 (0.00 to 0.07)	16.19
Fesoterodine 6mg	Dry eye	NCT00444925[56]	9/685	6/337	0.18 (0.10 to 0.26)	16.16	0.08 (0.03 to 0.13)	16.16
Fesoterodine 8mg	Dry eye	Chapple, 2007[253]	12/288	0/285	0.04 (-0.03 to 0.11)	17.56	0.00 (0.00 to 0.01)	17.56
Fesoterodine 8mg	Dry eye	Nitti, 2007[353]	9/279	0/274	-0.02 (-0.08 to 0.05)	17.62	0.00 (0.01 to 0.00)	17.62
Fesoterodine	Dry eye	Pooled	51/2245	14/1900	0.10 (0.03 to 0.18)	100	0.03 (0.01 to 0.06)	100
Fesoterodine	Dry eye	Heterogeneity			p value 0	81.60%	I-squared	81.60%
Fesoterodine 6mg	Treatment failure	Dmochowski, 2010[469]	14/438	29/445	-0.08 (-0.14 to -0.01)	49.65	-0.03 (-0.05 to -0.01)	49.65
Fesoterodine 6mg	Treatment failure	Herschorn, 2010[470]	32/679	34/334	-0.11 (-0.17 to -0.04)	50.35	-0.06 (-0.08 to -0.02)	50.35

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine	Treatment failure	Pooled	46/1117	63/779	-0.09 (-0.14 to -0.05)	100	-0.04 (-0.06 to -0.02)	100
Fesoterodine	Treatment failure	Heterogeneity			p value 0.511	0.00%	I-squared	0.00%
Fesoterodine 6mg	Fatigue	NCT00444925[56]	12/685	0/337	0.13 (0.07 to 0.20)	50.58	0.02 (0.00 to 0.04)	50.58
Fesoterodine 6mg	Fatigue	NCT00536484[57]	11/438	2/445	0.09 (0.03 to 0.16)	49.42	0.02 (0.00 to 0.05)	49.42
Fesoterodine	Fatigue	Pooled	23/1123	2/782	0.11 (0.07 to 0.16)	100	0.02 (0.01 to 0.04)	100
Fesoterodine	Fatigue	Heterogeneity			p value 0.39	0.00%	I-squared	0.00%
Fesoterodine 4mg	Headache	Chapple, 2004[261]	32/186	29/183	0.01 (-0.09 to 0.12)	7.7	0.01 (-0.06 to 0.09)	7.7
Fesoterodine 4mg	Headache	Chapple, 2007[253]	12/272	14/285	0.00 (-0.10 to 0.10)	7.45	0.00 (-0.03 to 0.05)	7.45
Fesoterodine 4mg	Headache	Nitti, 2007[353]	12/283	9/274	-0.01 (-0.12 to 0.09)	7.7	0.00 (-0.03 to 0.04)	7.7
Fesoterodine 6mg	Headache	Dmochowski, 2010[469]	19/438	15/445	-0.01 (-0.10 to 0.07)	11.07	0.00 (-0.03 to 0.03)	11.07
Fesoterodine 6mg	Headache	Herschorn, 2010[470]	38/679	8/334	-0.07 (-0.15 to 0.02)	11.35	-0.02 (-0.02 to 0.00)	11.35
Fesoterodine 8mg	Headache	Chapple, 2004[261]	28/173	29/183	0.03 (-0.06 to 0.11)	11.08	0.02 (-0.04 to 0.09)	11.08
Fesoterodine 8mg	Headache	Chapple, 2007[253]	7/288	14/285	-0.01 (-0.10 to 0.07)	11.01	-0.01 (-0.03 to 0.04)	11.01
Fesoterodine 8mg	Headache	Nitti, 2007[353]	8/279	9/274	0.03 (-0.04 to 0.09)	16.22	0.01 (-0.01 to 0.04)	16.22
Fesoterodine 12mg	Headache	Chapple, 2004[261]	28/186	29/183	0.08 (0.02 to 0.15)	16.41	0.07 (0.01 to 0.12)	16.41
Fesoterodine	Headache	Pooled	183/2784	157/2446	0.01 (-0.02 to 0.04)	100	0.00 (-0.01 to 0.02)	100
Fesoterodine	Headache	Heterogeneity			p value 0.316	14.10%	I-squared	14.10%
Fesoterodine 4mg	Nasopharyngitis	Chapple, 2007[253]	8/272	7/285	0.02 (-0.07 to 0.10)	13.83	0.00 (-0.02 to 0.04)	13.83
Fesoterodine 4mg	Nasopharyngitis	Nitti, 2007[353]	10/283	7/274	-0.03 (-0.11 to 0.06)	14.23	-0.01 (-0.02 to 0.02)	14.23

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Nasopharyngitis	NCT00444925[56]	13/685	10/337	0.03 (-0.05 to 0.11)	13.83	0.01 (-0.02 to 0.05)	13.83
Fesoterodine 6mg	Nasopharyngitis	NCT00536484[57]	19/438	25/445	-0.08 (-0.16 to 0.01)	13.73	-0.03 (-0.05 to 0.00)	13.73
Fesoterodine 8mg	Nasopharyngitis	Chapple, 2007[253]	5/288	7/285	-0.04 (-0.10 to 0.03)	22.44	-0.01 (-0.02 to 0.01)	22.44
Fesoterodine 8mg	Nasopharyngitis	Nitti, 2007[353]	2/279	7/274	-0.03 (-0.10 to 0.04)	21.93	-0.01 (-0.02 to 0.01)	21.93
Fesoterodine	Nasopharyngitis	Pooled	57/2245	63/1900	-0.02 (-0.05 to 0.01)	100	-0.01 (-0.02 to 0.00)	100
Fesoterodine	Nasopharyngitis	Heterogeneity			p value 0.551	0.00%	I-squared	0.00%
Fesoterodine 4mg	Abnormal vision	Chapple, 2004[261]	0/186	2/183	-0.10 (-0.20 to 0.00)	33.66	-0.01 (0.00 to 0.00)	33.66
Fesoterodine 8mg	Abnormal vision	Chapple, 2004[261]	0/173	2/183	-0.10 (-0.20 to 0.00)	32.67	-0.01 (0.00 to 0.00)	32.67
Fesoterodine 12mg	Abnormal vision	Chapple, 2004[261]	2/186	2/183	0.00 (-0.10 to 0.10)	33.66	0.00 (-0.01 to 0.03)	33.66
Fesoterodine	Abnormal vision	Pooled	2/545	5/549	-0.07 (-0.13 to 0.00)	100	-0.01 (-0.01 to 0.00)	100
Fesoterodine	Abnormal vision	Heterogeneity			p value 0.293	18.50%	I-squared	18.50%
Fesoterodine 4mg	Nausea	Chapple, 2004[261]	9/186	13/183	-0.04 (-0.14 to 0.06)	8.53	-0.02 (-0.05 to 0.03)	8.53
Fesoterodine 4mg	Nausea	Chapple, 2007[253]	1/272	1/285	-0.13 (-0.23 to -0.02)	8.31	0.00 (0.03 to 0.00)	8.31
Fesoterodine 4mg	Nausea	Nitti, 2007353	3/283	6/274	-0.02 (-0.12 to 0.08)	8.53	-0.01 (-0.02 to 0.03)	8.53
Fesoterodine 6mg	Nausea	NCT00444925[56]	12/685	6/337	0.00 (-0.08 to 0.08)	11.25	0.00 (-0.02 to 0.03)	11.25
Fesoterodine 6mg	Nausea	NCT00536484[57]	6/438	18/445	0.06 (-0.02 to 0.14)	11.46	0.03 (-0.01 to 0.07)	11.46
Fesoterodine 8mg	Nausea	Chapple, 2004[261]	3/173	13/183	-0.05 (-0.13 to 0.04)	11.25	-0.02 (-0.05 to 0.02)	11.25
Fesoterodine 8mg	Nausea	Chapple, 2007[253]	4/288	1/285	0.01 (-0.07 to 0.09)	11.2	0.00 (0.00 to 0.02)	11.2
Fesoterodine 8mg	Nausea	Nitti, 2007[353]	7/279	6/274	0.00 (-0.07 to 0.06)	14.82	0.00 (-0.02 to 0.02)	14.82

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 12mg	Nausea	Chapple, 2004[261]	11/186	13/183	-0.09 (-0.15 to -0.02)	14.64	-0.04 (-0.06 to -0.01)	14.64
Fesoterodine	Nausea	Pooled	57/2790	76/2449	-0.03 (-0.06 to 0.01)	100	-0.01 (-0.02 to 0.00)	100
Fesoterodine	Nausea	Heterogeneity			p value 0.119	37.50%	I-squared	37.50%
Fesoterodine 6mg	Serious adverse effects	NCT00444925[56]	15/685	8/337	-0.01 (-0.07 to 0.06)	50.58	0.00 (-0.02 to 0.02)	50.58
Fesoterodine 6mg	Serious adverse effects	NCT00536484[57]	5/438	7/445	-0.02 (-0.09 to 0.05)	49.42	0.00 (-0.01 to 0.01)	49.42
Fesoterodine	Serious adverse effects	Pooled	20/1123	15/782	-0.01 (-0.06 to 0.03)	100	0.00 (-0.01 to 0.01)	100
Fesoterodine	Serious adverse effects	Heterogeneity			p value 0.791	0.00%	I-squared	0.00%
Fesoterodine 6mg	Upper respiratory tract infection	NCT00444925[56]	2/685	4/337	-0.06 (-0.12 to 0.01)	50.58	-0.01 (-0.01 to 0.00)	50.58
Fesoterodine 6mg	Upper respiratory tract infection	NCT00536484[57]	21/438	23/445	-0.01 (-0.08 to 0.06)	49.42	0.00 (-0.03 to 0.03)	49.42
Fesoterodine	Upper respiratory tract infection	Pooled	23/1123	27/782	-0.03 (-0.08 to 0.01)	100	-0.01 (-0.02 to 0.01)	100
Fesoterodine	Upper respiratory tract infection	Heterogeneity			p value 0.326	0.00%	I-squared	0.00%
Fesoterodine 6mg	Urinary tract infection	Herschorn, 2010[470]	15/679	2/334	0.07 (0.01 to 0.14)	50.08	0.02 (0.00 to 0.04)	50.08
Fesoterodine 6mg	Urinary tract infection	NCT00536484[57]	8/438	12/445	-0.03 (-0.10 to 0.04)	49.92	-0.01 (-0.02 to 0.01)	49.92
Fesoterodine	Urinary tract infection	Pooled	23/1117	14/779	0.02 (-0.08 to 0.12)	100	0.01 (-0.01 to 0.05)	100
Fesoterodine	Urinary tract infection	Heterogeneity			p value 0.034	77.80%	I-squared	77.80%
Fesoterodine 4mg	Influenza-like symptoms	Chapple, 2004[261]	17/186	15/183	0.02 (-0.08 to 0.12)	33.64	0.01 (-0.04 to 0.08)	33.64

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 8mg	Influenza-like symptoms	Chapple, 2004[261]	7/173	15/183	-0.09 (-0.19 to 0.02)	32.71	-0.04 (-0.07 to 0.01)	32.71
Fesoterodine 12mg	Influenza-like symptoms	Chapple, 2004[261]	7/186	15/183	-0.09 (-0.19 to 0.02)	33.64	-0.04 (-0.07 to 0.01)	33.64
Fesoterodine	Influenza-like symptoms	Pooled	31/545	44/549	-0.05 (-0.12 to 0.02)	100	-0.03 (-0.05 to 0.01)	100
Fesoterodine	Influenza-like symptoms	Heterogeneity			p value 0.271	23.40%	I-squared	23.40%
Fesoterodine 4mg	Adverse effects	Chapple, 2007[253]	135/272	107/285	0.12 (0.04 to 0.21)	15.34	0.12 (0.04 to 0.20)	15.34
Fesoterodine 4mg	Adverse effects	Nitti, 2007353	171/283	149/274	0.21 (0.12 to 0.29)	15.58	0.20 (0.12 to 0.26)	15.58
Fesoterodine 6mg	Adverse effects	NCT00444925[56]	290/685	76/337	0.06 (-0.02 to 0.14)	15.34	0.05 (-0.02 to 0.13)	15.34
Fesoterodine 6mg	Adverse effects	NCT00536484[57]	199/438	130/445	0.15 (0.07 to 0.24)	15.28	0.15 (0.07 to 0.23)	15.28
Fesoterodine 8mg	Adverse effects	Chapple, 2007[253]	167/288	107/285	0.21 (0.15 to 0.28)	19.32	0.21 (0.15 to 0.28)	19.32
Fesoterodine 8mg	Adverse effects	Nitti, 2007[353]	193/279	149/274	0.17 (0.10 to 0.24)	19.14	0.16 (0.10 to 0.22)	19.14
Fesoterodine	Adverse effects	Pooled	1155/2245	718/1900	0.16 (0.11 to 0.20)	100	0.16 (0.11 to 0.20)	100
Fesoterodine		Heterogeneity			p value 0.071	50.70%	I-squared	50.70%
Fesoterodine 4mg	Back pain	Chapple, 2004[261]	6/186	5/183	0.00 (-0.10 to 0.10)	18.47	0.00 (-0.02 to 0.04)	18.47
Fesoterodine 6mg	Back pain	NCT00444925[56]	10/685	10/337	0.03 (-0.08 to 0.13)	17.81	0.01 (-0.02 to 0.06)	17.81
Fesoterodine 8mg	Back pain	Chapple, 2004[261]	7/173	5/183	-0.03 (-0.13 to 0.07)	18.47	-0.01 (-0.03 to 0.03)	18.47
Fesoterodine 12mg	Back pain	Chapple, 2004[261]	4/186	5/183	-0.05 (-0.12 to 0.01)	45.24	-0.02 (-0.03 to 0.00)	45.24
Fesoterodine	Back pain	Pooled	26/1230	26/886	-0.03 (-0.07 to 0.02)	100	-0.01 (-0.02 to 0.01)	100
Fesoterodine	Back pain	Heterogeneity			p value 0.598	0.00%	I-squared	0.00%
Fesoterodine 4mg	Constipation	Chapple, 2004[261]	4/186	5/183	-0.03 (-0.13 to 0.07)	9.64	-0.01 (-0.03 to 0.03)	9.64

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 4mg	Constipation	Chapple, 2007[253]	9/272	4/285	0.00 (-0.10 to 0.10)	9.6	0.00 (-0.01 to 0.03)	9.6
Fesoterodine 4mg	Constipation	Nitti, 2007[353]	14/283	7/274	0.07 (-0.03 to 0.18)	9.64	0.03 (-0.01 to 0.08)	9.64
Fesoterodine 6mg	Constipation	Dmochowski, 2010[469]	48/438	25/445	0.06 (-0.02 to 0.15)	10.01	0.03 (-0.01 to 0.09)	10.01
Fesoterodine 6mg	Constipation	Herschorn, 2010[470]	37/679	10/334	0.10 (0.01 to 0.18)	10.03	0.04 (0.00 to 0.09)	10.03
Fesoterodine 6mg	Constipation	Kaplan, 2010[318]	270/963	10/480	0.06 (-0.02 to 0.15)	10.01	0.02 (0.00 to 0.06)	10.01
Fesoterodine 8mg	Constipation	Chapple, 2004[261]	5/173	5/183	0.12 (0.03 to 0.20)	10.01	0.05 (0.01 to 0.10)	10.01
Fesoterodine 8mg	Constipation	Chapple, 2007[253]	13/288	4/285	0.10 (0.03 to 0.16)	10.3	0.03 (0.01 to 0.06)	10.3
Fesoterodine 8mg	Constipation	Nitti, 2007[353]	21/279	7/274	0.06 (-0.01 to 0.13)	10.31	0.02 (0.00 to 0.05)	10.31
Fesoterodine 12mg	Constipation	Chapple, 2004[261]	11/186	5/183	0.42 (0.36 to 0.47)	10.46	0.28 (0.23 to 0.33)	10.46
Fesoterodine	Constipation	Pooled	431/3747	83/2926	0.10 (0.00 to 0.19)	100	0.04 (0.00 to 0.10)	100
Fesoterodine	Constipation	Heterogeneity			p value 0	93.20%	I-squared	93.20%
Fesoterodine 4mg	Cough	Chapple, 2004[261]	6/186	7/183	-0.03 (-0.13 to 0.08)	17.42	-0.01 (-0.03 to 0.03)	17.42
Fesoterodine 6mg	Cough	NCT00444925[56]	8/685	1/337	-0.10 (-0.21 to 0.00)	17.12	0.00 (0.02 to 0.00)	17.12
Fesoterodine 6mg	Cough	NCT00536484[57]	9/438	2/445	-0.03 (-0.13 to 0.08)	17.42	0.00 (0.00 to 0.02)	17.42
Fesoterodine 8mg	Cough	Chapple, 2004[261]	2/173	7/183	0.05 (-0.01 to 0.12)	24.09	0.02 (0.00 to 0.06)	24.09
Fesoterodine 12mg	Cough	Chapple, 2004[261]	6/186	7/183	0.08 (0.01 to 0.14)	23.94	0.04 (0.00 to 0.07)	23.94
Fesoterodine	Cough	Pooled	30/1668	25/1331	0.00 (-0.06 to 0.07)	100	0.00 (-0.01 to 0.02)	100
Fesoterodine	Cough	Heterogeneity			p value 0.03	62.80%	I-squared	62.80%
Fesoterodine 6mg	Diarrhea	Herschorn, 2010[470]	14/679	4/334	0.04 (-0.03 to 0.10)	50.08	0.01 (-0.01 to 0.03)	50.08

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Diarrhea	NCT00536484[57]	9/438	19/445	-0.06 (-0.13 to 0.00)	49.92	-0.02 (-0.04 to 0.00)	49.92
Fesoterodine	Diarrhea	Pooled	23/1117	23/779	-0.01 (-0.11 to 0.08)	100	0.00 (-0.03 to 0.03)	100
Fesoterodine	Diarrhea	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Fesoterodine 4mg	Treatment discontinuation	Chapple, 2007[253]	41/272	33/285	0.05 (-0.03 to 0.14)	13.86	0.04 (-0.02 to 0.10)	13.86
Fesoterodine 4mg	Treatment discontinuation	Nitti, 2007[353]	58/283	41/274	0.01 (-0.07 to 0.10)	14.26	0.01 (-0.05 to 0.07)	14.26
Fesoterodine 6mg	Treatment discontinuation	Dmochowski, 2010[469]	56/438	60/445	0.07 (-0.01 to 0.16)	13.86	0.05 (-0.01 to 0.12)	13.86
Fesoterodine 6mg	Treatment discontinuation	Herschorn, 2010[470]	81/679	30/334	0.07 (-0.02 to 0.15)	13.76	0.04 (-0.01 to 0.10)	13.76
Fesoterodine 8mg	Treatment discontinuation	Chapple, 2007[253]	36/288	33/285	-0.01 (-0.08 to 0.06)	21.98	-0.01 (-0.04 to 0.04)	21.98
Fesoterodine 8mg	Treatment discontinuation	Nitti, 2007[353]	56/279	41/274	0.05 (-0.02 to 0.11)	22.29	0.04 (-0.01 to 0.09)	22.29
Fesoterodine	Treatment discontinuation	Pooled	328/2239	238/1897	0.04 (0.01 to 0.07)	100	0.03 (0.00 to 0.05)	100
Fesoterodine	Treatment discontinuation	Heterogeneity			p value 0.59	0.00%	I-squared	0.00%
Fesoterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	11/186	7/183	0.05 (-0.06 to 0.15)	12.89	0.02 (-0.02 to 0.08)	12.89
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Dmochowski, 2010[469]	34/438	21/445	-0.06 (-0.16 to 0.04)	12.61	-0.02 (-0.04 to 0.02)	12.61
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	44/679	6/334	0.15 (0.05 to 0.25)	12.89	0.06 (0.02 to 0.13)	12.89

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Fesoterodine 6mg	Treatment discontinuation due to adverse effects	Kaplan, 2010[318]	48/963	10/480	0.06 (0.00 to 0.13)	19.64	0.02 (0.00 to 0.05)	19.64
Fesoterodine 8mg	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	3/173	7/183	0.12 (0.06 to 0.19)	19.74	0.06 (0.03 to 0.10)	19.74
Fesoterodine 12mg	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	22/186	7/183	0.08 (0.03 to 0.14)	22.23	0.04 (0.01 to 0.07)	22.23
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled	163/2625	59/1808	0.07 (0.03 to 0.12)	100	0.03 (0.01 to 0.06)	100
Fesoterodine	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.048	55.30%	I-squared	55.30%
Oxybutynin 3.9mg	Adverse effects	Dmochowski, 2003[274]	7/121	13/117	0.31 (0.17 to 0.45)	32.45	0.25 (0.12 to 0.39)	32.45
Oxybutynin 9mg	Adverse effects	Homma, 200 [307]	30/244	4/122	-0.10 (-0.22 to 0.03)	33.28	-0.03 (-0.03 to 0.01)	33.28
Oxybutynin 10mg	Adverse effects	Madersbacher, 1999[343]	104/145	30/72	0.18 (0.07 to 0.28)	34.28	0.18 (0.07 to 0.28)	34.28
Oxybutynin	Adverse effects	Pooled	141/510	47/311	0.13 (-0.10 to 0.35)	100	0.10 (-0.06 to 0.31)	100
Oxybutynin	Adverse effects	Heterogeneity			p value 0	89.50%	I-squared	89.50%
Oxybutynin 5mg	Dyspepsia	Chancellor, 2001[249]	1/36	0/36	0.27 (0.11 to 0.43)	31.24	0.07 (0.01 to 0.17)	31.24
Oxybutynin 9mg	Dyspepsia	Homma, 2003[307]	20/244	4/122	0.17 (-0.06 to 0.40)	16.81	0.08 (-0.02 to 0.27)	16.81
Oxybutynin 15mg	Dyspepsia	Abrams, 1998[219]	27/118	3/57	0.11 (0.00 to 0.22)	51.95	0.06 (0.00 to 0.14)	51.95

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Dyspepsia	Pooled	48/398	7/215	0.17 (0.07 to 0.27)	100	0.08 (0.03 to 0.16)	100
Oxybutynin	Dyspepsia	Heterogeneity			p value 0.267	24.30%	I-squared	24.30%
Oxybutynin 3.9mg	Dysuria	Dmochowski, 2002[271]	3/125	0/132	0.16 (0.03 to 0.28)	44.52	0.02 (0.00 to 0.08)	44.52
Oxybutynin 10mg	Dysuria	Staskin, 2009[31]	1/389	1/400	0.00 (-0.07 to 0.07)	55.48	0.00 (0.00 to 0.01)	55.48
Oxybutynin	Dysuria	Pooled	4/514	1/532	0.07 (-0.08 to 0.22)	100	0.01 (0.00 to 0.07)	100
Oxybutynin	Dysuria	Heterogeneity			p value 0.031	78.50%	I-squared	78.50%
Oxybutynin 7.5mg	Treatment failure	Wang, 2006[413]	14/23	19/21	-0.26 (-0.44 to -0.07)	17.01	-0.20 (-0.37 to -0.05)	17.01
Oxybutynin 9mg	Treatment failure	Homma, 2003[307]	12/244	10/122	-0.09 (-0.27 to 0.08)	18.87	-0.04 (-0.08 to 0.05)	18.87
Oxybutynin 10mg	Treatment failure	Madersbacher, 1999[343]	28/145	23/72	-0.15 (-0.29 to -0.01)	24.13	-0.13 (-0.23 to -0.01)	24.13
Oxybutynin 11.5mg	Treatment failure	Burgio, 1998[238]	1/67	3/65	-0.06 (-0.17 to 0.05)	32.1	-0.02 (-0.04 to 0.02)	32.1
Oxybutynin 15mg	Treatment failure	Thuroff, 1991[386]	11/63	21/52	-0.36 (-0.66 to -0.07)	7.9	-0.30 (-0.41 to -0.06)	7.9
Oxybutynin	Treatment failure	Pooled	66/542	76/332	-0.15 (-0.24 to -0.06)	100	-0.11 (-0.16 to -0.05)	100
Oxybutynin	Treatment failure	Heterogeneity			p value 0.201	33.10%	I-squared	33.10%
Oxybutynin 5mg	Headache	Chancellor, 2001[249]	6/36	4/36	0.08 (-0.15 to 0.31)	5.72	0.06 (-0.08 to 0.26)	5.72
Oxybutynin 9mg	Headache	Homma, 2003[307]	11/244	8/122	0.08 (-0.15 to 0.31)	5.72	0.05 (-0.05 to 0.23)	5.72
Oxybutynin 10mg	Headache	Chancellor, 2001[249]	6/36	4/36	-0.05 (-0.15 to 0.06)	25.86	-0.03 (-0.08 to 0.04)	25.86
Oxybutynin 10mg	Headache	Staskin, 2009[31]	6/389	11/400	-0.04 (-0.11 to 0.03)	62.7	-0.01 (-0.02 to 0.01)	62.7
Oxybutynin	Headache	Pooled	29/705	27/594	-0.03 (-0.08 to 0.03)	100	-0.01 (-0.03 to 0.01)	100
Oxybutynin	Headache	Heterogeneity			p value 0.583	0.00%	I-squared	0.00%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin 3mg	Nausea	Moore, 1990[351]	4/48	1/43	0.45 (0.22 to 0.69)	9.31	0.30 (0.11 to 0.53)	9.31
Oxybutynin 3.9mg	Nausea	Dmochowski, 2002[271]	2/125	7/132	0.14 (-0.07 to 0.35)	10.64	0.08 (-0.03 to 0.25)	10.64
Oxybutynin 5mg	Nausea	Chancellor, 2001[249]	1/36	1/36	-0.08 (-0.24 to 0.07)	13.21	-0.02 (-0.02 to 0.03)	13.21
Oxybutynin 10mg	Nausea	Madersbacher, 1999[343]	14/145	6/72	0.03 (-0.11 to 0.17)	14.2	0.02 (-0.05 to 0.12)	14.2
Oxybutynin 10mg	Nausea	Chancellor, 2001[249]	0/36	1/36	0.00 (-0.23 to 0.23)	9.47	0.00 (-0.02 to 0.12)	9.47
Oxybutynin 10mg	Nausea	Staskin, 2009[31]	1/389	2/400	-0.17 (-0.40 to 0.06)	9.47	0.00 (0.10 to 0.01)	9.47
Oxybutynin 15mg	Nausea	Abrams, 1998[219]	7/118	6/57	-0.11 (-0.23 to 0.02)	15.35	-0.06 (-0.09 to 0.01)	15.35
Oxybutynin 20mg	Nausea	Tapp, 1990[384]	7/37	0/33	-0.02 (-0.09 to 0.05)	18.34	0.00 (0.01 to 0.00)	18.34
Oxybutynin	Nausea	Pooled	36/934	24/809	0.01 (-0.08 to 0.11)	100	0.00 (-0.02 to 0.05)	100
Oxybutynin	Nausea	Heterogeneity			p value 0.002	68.40%	I-squared	68.40%
Oxybutynin 9mg	Retention	Homma, 2003[307]	8/244	0/122	0.30 (0.13 to 0.47)	30.03	0.09 (0.02 to 0.21)	30.03
Oxybutynin 10mg	Retention	Staskin, 200931	0/389	1/400	0.18 (0.07 to 0.29)	34.03	0.05 (0.01 to 0.11)	34.03
Oxybutynin 11.5mg	Retention	Burgio, 1998[238]	14/67	2/65	-0.05 (-0.12 to 0.02)	35.94	-0.02 (-0.03 to 0.01)	35.94
Oxybutynin	Retention	Pooled	22/700	3/587	0.14 (-0.08 to 0.35)	100	0.04 (-0.01 to 0.16)	100
Oxybutynin	Retention	Heterogeneity			p value 0	90.90%	I-squared	90.90%
Oxybutynin 3.9mg	Serious adverse effects	Dmochowski, 2003[274]	1/121	3/117	-0.07 (-0.20 to 0.06)	32.04	-0.02 (-0.02 to 0.02)	32.04
Oxybutynin 9mg	Serious adverse effects	Homma, 2003[307]	20/244	0/122	0.29 (0.18 to 0.40)	33.08	0.08 (0.03 to 0.15)	33.08
Oxybutynin 10mg	Serious adverse effects	Staskin, 2009[31]	7/389	10/400	-0.02 (-0.09 to 0.05)	34.89	-0.01 (-0.02 to 0.02)	34.89
Oxybutynin	Serious adverse effects	Pooled	28/754	13/639	0.07 (-0.15 to 0.28)	100	0.02 (-0.02 to 0.15)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Serious adverse effects	Heterogeneity			p value 0	92.50%	I-squared	92.50%
Oxybutynin 3.9mg	Somnolence	Dmochowski, 2002[271]	2/125	1/132	0.04 (-0.08 to 0.16)	22.13	0.01 (-0.01 to 0.05)	22.13
Oxybutynin 9mg	Somnolence	Homma, 2003[307]	4/244	4/122	-0.05 (-0.16 to 0.06)	26.88	-0.02 (-0.03 to 0.02)	26.88
Oxybutynin 10mg	Somnolence	Staskin, 2009[31]	1/389	0/400	0.05 (-0.02 to 0.12)	51	0.00 (0.00 to 0.01)	51
Oxybutynin	Somnolence	Pooled	7/758	5/654	0.02 (-0.04 to 0.08)	100	0.00 (-0.01 to 0.02)	100
Oxybutynin	Somnolence	Heterogeneity			p value 0.274	22.80%	I-squared	22.80%
Oxybutynin 3.9mg	Vision disorder	Dmochowski, 2002[271]	0/125	2/132	0.13 (-0.06 to 0.31)	28.4	0.05 (-0.01 to 0.16)	28.4
Oxybutynin 10mg	Vision disorder	Madersbacher, 1999[343]	26/145	10/72	0.06 (-0.09 to 0.20)	34.38	0.04 (-0.05 to 0.16)	34.38
Oxybutynin 15mg	Vision disorder	Thuroff, 1991[386]	1/63	0/52	-0.12 (-0.25 to 0.00)	37.22	0.02 (0.06 to 0.00)	37.22
Oxybutynin	Vision disorder	Pooled	27/333	12/256	0.01 (-0.14 to 0.16)	100	0.00 (-0.04 to 0.09)	100
Oxybutynin	Vision disorder	Heterogeneity			p value 0.045	67.90%	I-squared	67.90%
Oxybutynin 5mg	Blurred vision	Szonyi, 1995[382]	14/28	17/29	0.31 (0.07 to 0.54)	15.51	0.27 (0.07 to 0.39)	15.51
Oxybutynin 9mg	Blurred vision	Homma, 2003[307]	8/244	0/122	-0.09 (-0.35 to 0.17)	13.28	0.01 (0.12 to 0.03)	13.28
Oxybutynin 11.5mg	Blurred vision	Burgio, 1998[238]	10/67	6/65	0.09 (-0.08 to 0.26)	23.98	0.06 (-0.04 to 0.20)	23.98
Oxybutynin 15mg	Blurred vision	Zinner, 2005[405]	1/19	0/19	0.18 (0.07 to 0.29)	37.71	0.03 (0.01 to 0.08)	37.71
Oxybutynin 20mg	Blurred vision	Tapp, 1990[384]	8/37	1/33	0.18 (-0.14 to 0.50)	9.53	0.09 (-0.03 to 0.36)	9.53
Oxybutynin	Blurred vision	Pooled	41/395	24/268	0.14 (0.04 to 0.25)	100	0.10 (0.02 to 0.19)	100
Oxybutynin	Blurred vision	Heterogeneity			p value 0.202	32.90%	I-squared	32.90%
Oxybutynin 5mg	Vomiting	Chancellor, 2001[249]	2/36	0/36	-0.05 (-0.19 to 0.09)	40.89	0.00 (0.04 to 0.01)	40.89

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin 10mg	Vomiting	Madersbacher, 1999[343]	2/145	2/72	0.24 (0.01 to 0.47)	29.56	0.13 (0.00 to 0.33)	29.56
Oxybutynin 10mg	Vomiting	Chancellor, 2001[249]	1/36	0/36	0.17 (-0.06 to 0.40)	29.56	0.03 (0.00 to 0.15)	29.56
Oxybutynin	Vomiting	Pooled	5/217	2/144	0.10 (-0.09 to 0.29)	100	0.03 (-0.01 to 0.14)	100
Oxybutynin	Vomiting	Heterogeneity			p value 0.067	63.10%	I-squared	63.10%
Oxybutynin 3mg	Constipation	Moore, 1990[351]	6/48	0/43	0.19 (-0.04 to 0.43)	9.47	0.04 (0.00 to 0.17)	9.47
Oxybutynin 3.9mg	Constipation	Dmochowski, 2002[271]	1/125	4/132	0.36 (0.16 to 0.57)	11.12	0.23 (0.08 to 0.43)	11.12
Oxybutynin 9mg	Constipation	Homma, 2003[307]	15/244	6/122	0.01 (-0.16 to 0.19)	13.57	0.01 (-0.04 to 0.11)	13.57
Oxybutynin 10mg	Constipation	Staskin, 2009[31]	5/389	4/400	-0.09 (-0.21 to 0.04)	17.78	-0.01 (0.00 to 0.01)	17.78
Oxybutynin 11.5mg	Constipation	Burgio, 1998[238]	26/67	24/65	0.03 (-0.08 to 0.14)	19.09	0.03 (-0.08 to 0.13)	19.09
Oxybutynin 15mg	Constipation	Zinner, 2005[405]	2/19	1/19	0.11 (-0.21 to 0.43)	6.16	0.05 (-0.03 to 0.29)	6.16
Oxybutynin 20mg	Constipation	Tapp, 1990[384]	13/37	6/33	0.01 (-0.06 to 0.08)	22.81	0.01 (-0.04 to 0.07)	22.81
Oxybutynin	Constipation	Pooled	67/929	45/814	0.06 (-0.03 to 0.15)	100	0.03 (-0.01 to 0.09)	100
Oxybutynin	Constipation	Heterogeneity			p value 0.015	61.90%	I-squared	61.90%
Oxybutynin 5mg	Treatment discontinuation	Szonyi, 1995[382]	8/28	5/29	0.14 (-0.12 to 0.40)	4.72	0.11 (-0.08 to 0.37)	4.72
Oxybutynin 10mg	Treatment discontinuation	Madersbacher, 1999[343]	16/145	7/72	0.02 (-0.16 to 0.19)	10.92	0.01 (-0.07 to 0.14)	10.92
Oxybutynin 10mg	Treatment discontinuation	Staskin, 2009[31]	43/389	45/400	0.02 (-0.12 to 0.16)	15.93	0.01 (-0.06 to 0.12)	15.93
Oxybutynin 11.5mg	Treatment discontinuation	Burgio, 1998[238]	10/67	9/65	0.12 (-0.20 to 0.44)	3.15	0.09 (-0.11 to 0.40)	3.15
Oxybutynin 15mg	Treatment discontinuation	Zinner, 2005[405]	6/19	4/19	0.00 (-0.07 to 0.07)	65.29	0.00 (-0.06 to 0.06)	65.29
Oxybutynin	Treatment discontinuation	Pooled	83/648	70/585	0.01 (-0.04 to 0.07)	100	0.01 (-0.03 to 0.05)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Treatment discontinuation	Heterogeneity			p value 0.824	0.00%	I-squared	0.00%
Oxybutynin 9mg	Treatment discontinuation due to adverse effects	Homma, 2003[307]	42/244	11/122	0.18 (0.00 to 0.36)	15.58	0.13 (0.00 to 0.29)	15.58
Oxybutynin 10mg	Treatment discontinuation due to adverse effects	Staskin, 2009[31]	19/389	13/400	0.07 (-0.09 to 0.22)	18.53	0.03 (-0.02 to 0.12)	18.53
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Thuroff, 1991[386]	2/63	0/52	0.12 (0.01 to 0.23)	25.97	0.01 (0.00 to 0.05)	25.97
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Abrams, 1998[219]	20/118	7/57	0.48 (0.16 to 0.80)	6.98	0.43 (0.12 to 0.71)	6.98
Oxybutynin 15mg	Treatment discontinuation due to adverse effects	Zinner, 2005[405]	4/19	0/19	0.04 (-0.03 to 0.11)	32.93	0.00 (0.00 to 0.01)	32.93
Oxybutynin	Treatment discontinuation due to adverse	Pooled	87/833	31/650	0.12 (0.03 to 0.21)	100	0.06 (0.01 to 0.13)	100
Oxybutynin	Treatment discontinuation due to adverse	Heterogeneity			p value 0.066	54.60%	I-squared	54.60%
Oxybutynin 3mg	Dizziness	Moore, 1990[351]	2/48	3/43	-0.06 (-0.27 to 0.14)	6.05	-0.03 (-0.07 to 0.09)	6.05
Oxybutynin 3.9mg	Dizziness	Dmochowski, 2002[271]	5/125	5/132	0.01 (-0.12 to 0.13)	17.12	0.00 (-0.03 to 0.06)	17.12
Oxybutynin 9mg	Dizziness	Homma, 2003[307]	6/244	2/122	0.03 (-0.08 to 0.14)	21.69	0.01 (-0.01 to 0.05)	21.69
Oxybutynin 10mg	Dizziness	Staskin, 2009[31]	6/389	2/400	0.13 (-0.19 to 0.45)	2.53	0.03 (0.01 to 0.24)	2.53

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Oxybutynin	Dizziness	Zinner, 2005[405]	0/19	0/19	0.05 (-0.02 to 0.12)	52.6	0.00 (0.00 to 0.02)	52.6
Oxybutynin	Dizziness	Pooled	19/806	12/697	0.04 (-0.02 to 0.09)	100	0.01 (0.00 to 0.03)	100
Oxybutynin	Dizziness	Heterogeneity			p value 0.795	0.00%	I-squared	0.00%
Oxybutynin 3mg	Dry mouth	Moore, 1990[351]	42/48	14/43	0.50 (0.27 to 0.74)	10.52	0.48 (0.27 to 0.62)	10.52
Oxybutynin 2.6mg	Dry mouth	Dmochowski, 2002[271]	27/388	11/132	0.61 (0.40 to 0.81)	10.91	0.53 (0.32 to 0.71)	10.91
Oxybutynin 5mg	Dry mouth	Szonyi, 1995[382]	26/28	25/29	0.12 (-0.14 to 0.38)	10.16	0.07 (-0.11 to 0.14)	10.16
Oxybutynin 9mg	Dry mouth	Homma, 2003[307]	131/244	12/122	0.72 (0.56 to 0.88)	11.49	0.64 (0.49 to 0.77)	11.49
Oxybutynin 10mg	Dry mouth	Staskin, 2009[31]	27/389	11/400	0.56 (0.39 to 0.73)	11.34	0.41 (0.25 to 0.58)	11.34
Oxybutynin 11.5mg	Dry mouth	Burgio, 1998[238]	65/67	36/65	-0.02 (-0.12 to 0.07)	12.05	-0.02 (-0.12 to 0.07)	12.05
Oxybutynin 15mg	Dry mouth	Abrams, 1998[219]	102/118	12/57	0.50 (0.40 to 0.61)	11.97	0.48 (0.38 to 0.57)	11.97
Oxybutynin 15mg	Dry mouth	Zinner, 2005[405]	7/19	1/19	0.42 (0.10 to 0.74)	9.31	0.31 (0.05 to 0.62)	9.31
Oxybutynin 20mg	Dry mouth	Tapp, 1990[384]	29/37	10/33	0.10 (0.03 to 0.17)	12.24	0.10 (0.03 to 0.16)	12.24
Oxybutynin	Dry mouth	Pooled	456/1338	132/900	0.39 (0.19 to 0.58)	100	0.35 (0.16 to 0.54)	100
Oxybutynin	Dry mouth	Heterogeneity			p value 0	94.00%	I-squared	94.00%
Oxybutynin 5mg	Dry skin	Szonyi, 1995[382]	14/28	17/29	0.46 (0.23 to 0.69)	31.64	0.36 (0.20 to 0.41)	31.64
Oxybutynin 9mg	Dry skin	Homma, 2003[307]	4/244	1/122	-0.09 (-0.35 to 0.17)	30.17	-0.01 (0.06 to 0.06)	30.17
Oxybutynin 20mg	Dry skin	Tapp, 1990[384]	13/37	1/33	0.04 (-0.07 to 0.15)	38.19	0.01 (-0.02 to 0.07)	38.19
Oxybutynin	Dry skin	Pooled	31/309	19/184	0.13 (-0.15 to 0.42)	100	0.09 (-0.07 to 0.35)	100
Oxybutynin	Dry skin	Heterogeneity			p value 0.002	83.70%	I-squared	83.70%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Adverse effects	Chapple, 2004[260]	6/41	6/38	-0.02 (-0.24 to 0.21)	11.43	-0.01 (-0.13 to 0.17)	11.43
Solifenacin 5mg	Adverse effects	Chapple, 2004[260]	12/37	6/38	0.20 (-0.03 to 0.42)	11.05	0.17 (-0.02 to 0.39)	11.05
Solifenacin 7.5mg	Adverse effects	Karram, 2009[320]	160/372	88/367	0.22 (-0.01 to 0.45)	10.84	0.20 (-0.01 to 0.43)	10.84
Solifenacin 10mg	Adverse effects	Chapple, 2004[260]	12/35	6/38	0.45 (0.22 to 0.67)	11.05	0.41 (0.19 to 0.62)	11.05
Solifenacin 10mg	Adverse effects	Chu, 2009[264]	236/340	197/332	0.20 (0.13 to 0.28)	28.06	0.19 (0.12 to 0.24)	28.06
Solifenacin 20mg	Adverse effects	Chapple, 2004[260]	21/37	6/38	0.11 (0.03 to 0.18)	27.58	0.08 (0.02 to 0.15)	27.58
Solifenacin	Adverse effects	Pooled	447/862	309/851	0.18 (0.09 to 0.27)	100	0.18 (0.09 to 0.27)	100
Solifenacin	Adverse effects	Heterogeneity			p value 0.032	59.00%	I-squared	59.00%
Solifenacin 5mg	Dry mouth	Chapple, 2004[260]	5/37	0/38	0.38 (0.15 to 0.60)	4.74	0.13 (0.02 to 0.32)	4.74
Solifenacin 5mg	Dry mouth	Cardozo, 2006[412]	35/314	35/781	0.39 (0.16 to 0.62)	4.66	0.28 (0.09 to 0.50)	4.66
Solifenacin 5mg	Dry mouth	Staskin, 2006[37]	63/578	51/1216	0.66 (0.44 to 0.89)	4.74	0.54 (0.32 to 0.75)	4.74
Solifenacin 5mg	Dry mouth	Yamaguchi, 2007[403]	67/400	23/406	0.12 (0.06 to 0.19)	9.48	0.07 (0.03 to 0.12)	9.48
Solifenacin 7.5mg	Dry mouth	Cardozo, 2008[60]	80/641	6/224	0.36 (0.31 to 0.41)	9.87	0.22 (0.18 to 0.26)	9.87
Solifenacin 7.5mg	Dry mouth	Karram, 2009[320]	94/372	33/367	0.13 (0.08 to 0.18)	9.87	0.09 (0.05 to 0.13)	9.87
Solifenacin 7.5mg	Dry mouth	Vardy, 2009[392]	51/386	9/382	0.35 (0.31 to 0.39)	10.07	0.21 (0.17 to 0.24)	10.07
Solifenacin 10mg	Dry mouth	Chapple, 2004[260]	5/35	0/38	0.18 (0.11 to 0.25)	9.39	0.03 (0.01 to 0.06)	9.39
Solifenacin 10mg	Dry mouth	Cardozo, 2006[412]	226/778	35/781	0.38 (0.31 to 0.45)	9.37	0.27 (0.21 to 0.33)	9.37
Solifenacin 10mg	Dry mouth	Staskin, 2006[37]	340/1233	51/1216	0.20 (0.12 to 0.27)	9.19	0.11 (0.06 to 0.17)	9.19

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 10mg	Dry mouth	Yamaguchi, 2007[403]	130/385	23/406	0.22 (0.15 to 0.29)	9.3	0.14 (0.09 to 0.20)	9.3
Solifenacin 20mg	Dry mouth	Chapple, 2004[260]	14/37	0/38	0.22 (0.15 to 0.29)	9.34	0.05 (0.02 to 0.08)	9.34
Solifenacin	Dry mouth	Pooled	1110/5196	266/5893	0.27 (0.21 to 0.34)	100	0.17 (0.12 to 0.23)	100
Solifenacin	Dry mouth	Heterogeneity			p value 0	90.10%	I-squared	90.10%
Solifenacin 5mg	Dyspepsia	Chapple, 2004[260]	1/37	0/38	0.17 (-0.06 to 0.39)	6.55	0.03 (0.00 to 0.15)	6.55
Solifenacin 7.5mg	Dyspepsia	Vardy, 2009[392]	5/386	0/382	0.17 (-0.06 to 0.40)	6.38	0.03 (0.00 to 0.15)	6.38
Solifenacin 10mg	Dyspepsia	Chapple, 2004[260]	1/35	0/38	0.38 (0.15 to 0.60)	6.55	0.13 (0.02 to 0.32)	6.55
Solifenacin 10mg	Dyspepsia	Chu, 2009[264]	16/340	3/332	0.11 (0.04 to 0.19)	41.88	0.03 (0.01 to 0.07)	41.88
Solifenacin 20mg	Dyspepsia	Chapple, 2004[260]	5/37	0/38	0.12 (0.05 to 0.20)	38.65	0.02 (0.00 to 0.04)	38.65
Solifenacin	Dyspepsia	Pooled	28/835	3/828	0.14 (0.08 to 0.20)	100	0.04 (0.02 to 0.06)	100
Solifenacin	Dyspepsia	Heterogeneity			p value 0.292	19.20%	I-squared	19.20%
Solifenacin 5mg	Treatment failure	Chapple, 2004[52]	2/279	2/267	0.00 (-0.09 to 0.08)	24.12	0.00 (-0.01 to 0.02)	24.12
Solifenacin 7.5mg	Treatment failure	Cardozo, 2008[60]	298/641	147/224	-0.20 (-0.27 to -0.12)	24.97	-0.19 (-0.27 to -0.12)	24.97
Solifenacin 7.5mg	Treatment failure	Toglia, 2009[321]	112/372	191/367	-0.23 (-0.30 to -0.15)	25.38	-0.22 (-0.28 to -0.15)	25.38
Solifenacin 7.5mg	Treatment failure	Vardy, 2009[392]	53/386	115/382	-0.20 (-0.27 to -0.13)	25.53	-0.16 (-0.21 to -0.11)	25.53
Solifenacin	Treatment failure	Pooled	465/1678	455/1240	-0.16 (-0.25 to -0.06)	100	-0.14 (-0.22 to -0.06)	100
Solifenacin	Treatment failure	Heterogeneity			p value 0	84.10%	I-squared	84.10%
Solifenacin 7.5mg	Fatigue	Karram, 2009[320]	10/372	4/367	0.06 (-0.01 to 0.13)	49.04	0.02 (0.00 to 0.04)	49.04
Solifenacin 7.5mg	Fatigue	Vardy, 2009[392]	5/386	2/382	0.04 (-0.03 to 0.11)	50.96	0.01 (0.00 to 0.03)	50.96

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Fatigue	Pooled	15/758	6/749	0.05 (0.00 to 0.10)	100	0.01 (0.00 to 0.03)	100
Solifenacin	Fatigue	Heterogeneity			p value 0.722	0.00%	I-squared	0.00%
Solifenacin 2.5mg	Headache	Chapple, 2004[260]	0/41	1/38	-0.16 (-0.38 to 0.06)	3.18	-0.03 (0.02 to 0.02)	3.18
Solifenacin 5mg	Headache	Chapple, 2004[260]	2/37	1/38	0.07 (-0.16 to 0.30)	3.02	0.03 (-0.03 to 0.17)	3.02
Solifenacin 7.5mg	Headache	Karram, 2009[320]	17/372	19/367	0.08 (-0.15 to 0.31)	2.94	0.04 (-0.05 to 0.21)	2.94
Solifenacin 7.5mg	Headache	Vardy, 2009[392]	3/386	5/382	0.07 (-0.16 to 0.30)	3.02	0.02 (-0.01 to 0.15)	3.02
Solifenacin 10mg	Headache	Chapple, 2004[260]	2/35	1/38	-0.01 (-0.09 to 0.06)	29.79	0.00 (-0.02 to 0.02)	29.79
Solifenacin 10mg	Headache	Chu, 2009[264]	16/340	24/332	-0.03 (-0.10 to 0.04)	30.96	-0.01 (-0.04 to 0.02)	30.96
Solifenacin 20mg	Headache	Chapple, 2004[260]	2/37	1/38	-0.05 (-0.13 to 0.02)	27.09	-0.01 (-0.03 to 0.01)	27.09
Solifenacin	Headache	Pooled	42/1248	52/1233	-0.03 (-0.07 to 0.01)	100	-0.01 (-0.02 to 0.01)	100
Solifenacin	Headache	Heterogeneity			p value 0.633	0.00%	I-squared	0.00%
Solifenacin 7.5mg	Nausea	Vardy, 2009[392]	4/386	6/382	-0.02 (-0.09 to 0.05)	52.34	-0.01 (-0.01 to 0.01)	52.34
Solifenacin 10mg	Nausea	Chu, 2009[264]	19/340	13/332	0.04 (-0.04 to 0.12)	47.66	0.02 (-0.01 to 0.06)	47.66
Solifenacin	Nausea	Pooled	23/726	19/714	0.01 (-0.06 to 0.07)	100	0.00 (-0.01 to 0.03)	100
Solifenacin	Nausea	Heterogeneity			p value 0.232	30.00%	I-squared	30.00%
Solifenacin 10mg	Urinary retention	Chu, 2009[264]	7/340	3/332	0.24 (0.01 to 0.46)	32.85	0.10 (0.00 to 0.27)	32.85
Solifenacin 20mg	Urinary retention	Chapple, 2004[260]	2/37	0/38	0.05 (-0.03 to 0.12)	67.15	0.00 (0.00 to 0.02)	67.15
Solifenacin	Urinary retention	Pooled	9/377	3/370	0.11 (-0.06 to 0.28)	100	0.03 (-0.01 to 0.12)	100
Solifenacin	Urinary retention	Heterogeneity			p value 0.127	57.10%	I-squared	57.10%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Blurred vision	Chapple, 2004[260]	1/41	2/38	-0.08 (-0.30 to 0.15)	0.94	-0.03 (-0.05 to 0.08)	0.94
Solifenacin 5mg	Blurred vision	Chapple, 2004[260]	1/37	2/38	-0.07 (-0.29 to 0.16)	0.9	-0.03 (-0.05 to 0.09)	0.9
Solifenacin 5mg	Blurred vision	Chapple, 2004[52]	10/279	7/267	0.16 (-0.07 to 0.39)	0.87	0.07 (-0.02 to 0.25)	0.87
Solifenacin 5mg	Blurred vision	Cardozo, 2006[412]	13/314	14/781	0.15 (-0.08 to 0.37)	0.9	0.06 (-0.02 to 0.22)	0.9
Solifenacin 5mg	Blurred vision	Staskin, 2006[37]	22/578	22/1216	0.03 (-0.06 to 0.11)	5.4	0.01 (-0.01 to 0.04)	5.4
Solifenacin 5mg	Blurred vision	Yamaguchi, 2007[403]	7/400	8/406	0.08 (-0.01 to 0.16)	5.33	0.03 (0.00 to 0.07)	5.33
Solifenacin 7.5mg	Blurred vision	Cardozo, 2008[60]	4/641	2/224	0.07 (0.00 to 0.13)	7.86	0.02 (0.00 to 0.04)	7.86
Solifenacin 7.5mg	Blurred vision	Karram, 2009[320]	14/372	4/367	0.08 (0.03 to 0.13)	11.25	0.02 (0.01 to 0.04)	11.25
Solifenacin 7.5mg	Blurred vision	Vardy, 2009[392]	4/386	5/382	0.06 (0.01 to 0.11)	11.29	0.02 (0.00 to 0.04)	11.29
Solifenacin 10mg	Blurred vision	Chapple, 2004[260]	5/35	2/38	0.09 (0.05 to 0.13)	14.28	0.04 (0.02 to 0.07)	14.28
Solifenacin 10mg	Blurred vision	Chapple, 2004[52]	15/269	7/267	-0.01 (-0.08 to 0.06)	7.28	0.00 (-0.02 to 0.02)	7.28
Solifenacin 10mg	Blurred vision	Cardozo, 2006[412]	36/778	14/781	0.06 (-0.01 to 0.13)	7.18	0.02 (0.00 to 0.05)	7.18
Solifenacin 10mg	Blurred vision	Staskin, 2006[37]	59/1233	22/1216	-0.02 (-0.09 to 0.06)	6.3	0.00 (-0.02 to 0.02)	6.3
Solifenacin 10mg	Blurred vision	Yamaguchi, 2007[403]	16/385	8/406	0.09 (0.02 to 0.16)	6.83	0.03 (0.01 to 0.07)	6.83
Solifenacin 10mg	Blurred vision	Chu, 2009[264]	3/340	0/332	-0.01 (-0.08 to 0.06)	7.03	0.00 (0.01 to 0.00)	7.03
Solifenacin 20mg	Blurred vision	Chapple, 2004[260]	5/37	2/38	0.09 (0.02 to 0.17)	6.36	0.05 (0.01 to 0.10)	6.36
Solifenacin	Blurred vision	Pooled	215/6125	121/6797	0.06 (0.03 to 0.08)	100	0.02 (0.01 to 0.03)	100
Solifenacin	Blurred vision	Heterogeneity			p value 0.17	25.20%	I-squared	25.20%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 2.5mg	Constipation	Chapple, 2004[260]	1/41	0/38	0.16 (-0.06 to 0.38)	2.66	0.02 (0.00 to 0.14)	2.66
Solifenacin 5mg	Constipation	Cardozo, 2006[412]	20/314	28/781	0.24 (0.01 to 0.47)	2.5	0.14 (0.00 to 0.34)	2.5
Solifenacin 5mg	Constipation	Staskin, 2006[37]	31/578	35/1216	0.41 (0.19 to 0.64)	2.56	0.28 (0.09 to 0.50)	2.56
Solifenacin 5mg	Constipation	Yamaguchi, 2007[403]	42/400	16/406	0.07 (0.00 to 0.13)	9.13	0.03 (0.00 to 0.07)	9.13
Solifenacin 7.5mg	Constipation	Cardozo, 2008[60]	35/641	5/224	0.19 (0.14 to 0.24)	10.14	0.09 (0.06 to 0.12)	10.14
Solifenacin 7.5mg	Constipation	Karram, 2009[320]	55/372	34/367	0.06 (0.01 to 0.11)	10.15	0.04 (0.01 to 0.08)	10.15
Solifenacin 7.5mg	Constipation	Vardy, 2009[392]	31/386	7/382	0.20 (0.16 to 0.24)	10.72	0.09 (0.07 to 0.12)	10.72
Solifenacin 10mg	Constipation	Chapple, 2004[260]	2/35	0/38	0.13 (0.06 to 0.20)	8.9	0.02 (0.00 to 0.04)	8.9
Solifenacin 10mg	Constipation	Cardozo, 2006[412]	109/778	28/781	0.25 (0.18 to 0.32)	8.85	0.14 (0.09 to 0.20)	8.85
Solifenacin 10mg	Constipation	Staskin, 2006[37]	165/1233	35/1216	0.09 (0.01 to 0.16)	8.44	0.04 (0.00 to 0.08)	8.44
Solifenacin 10mg	Constipation	Yamaguchi, 2007[403]	72/385	16/406	0.09 (0.01 to 0.16)	8.7	0.04 (0.01 to 0.08)	8.7
Solifenacin 10mg	Constipation	Chu, 2009[264]	26/340	7/332	0.15 (0.08 to 0.22)	8.79	0.06 (0.03 to 0.11)	8.79
Solifenacin 20mg	Constipation	Chapple, 2004[260]	6/37	0/38	0.13 (0.06 to 0.21)	8.47	0.02 (0.00 to 0.04)	8.47
Solifenacin	Constipation	Pooled	595/5540	212/6225	0.15 (0.11 to 0.19)	100	0.07 (0.05 to 0.10)	100
Solifenacin	Constipation	Heterogeneity			p value 0	74.80%	I-squared	74.80%
Solifenacin 7.5mg	Death	Cardozo, 2008[60]	1/641	0/224	0.00 (-0.08 to 0.08)	31.26	0.00 (0.01 to 0.01)	31.26
Solifenacin 10mg	Death	Chapple, 2004[52]	1/269	0/267	0.06 (-0.02 to 0.15)	30.7	0.00 (0.00 to 0.02)	30.7
Solifenacin 5mg	Death	Chapple, 2004[52]	0/279	0/267	0.04 (-0.04 to 0.12)	38.03	0.00 (0.00 to 0.01)	38.03

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Death	Pooled	2/1189	0/758	0.03 (-0.01 to 0.08)	100	0.00 (0.00 to 0.01)	100
Solifenacin	Death	Heterogeneity			p value 0.594	0.00%	I-squared	0.00%
Solifenacin 5mg	Treatment discontinuation	Chapple, 2004[260]	3/37	6/38	-0.12 (-0.35 to 0.11)	1.6	-0.08 (-0.15 to 0.08)	1.6
Solifenacin 5mg	Treatment discontinuation	Chapple, 2004[52]	28/279	32/267	0.06 (-0.18 to 0.29)	1.56	0.04 (-0.09 to 0.24)	1.56
Solifenacin 5mg	Treatment discontinuation	Yamaguchi, 2007[403]	34/400	34/406	-0.03 (-0.12 to 0.05)	11.25	-0.02 (-0.05 to 0.03)	11.25
Solifenacin 7.5mg	Treatment discontinuation	Cardozo, 2008[60]	49/641	24/224	-0.08 (-0.16 to 0.01)	11.05	-0.04 (-0.08 to 0.00)	11.05
Solifenacin 7.5mg	Treatment discontinuation	Toglia, 2009[321]	9/372	18/367	0.00 (-0.07 to 0.07)	16.28	0.00 (-0.02 to 0.04)	16.28
Solifenacin 10mg	Treatment discontinuation	Chapple, 2004[260]	7/35	6/38	0.00 (-0.07 to 0.07)	15.99	0.00 (-0.05 to 0.05)	15.99
Solifenacin 10mg	Treatment discontinuation	Chapple, 2004[52]	20/269	32/267	-0.05 (-0.13 to 0.02)	13.56	-0.03 (-0.07 to 0.02)	13.56
Solifenacin 10mg	Treatment discontinuation	Yamaguchi, 2007[403]	32/385	34/406	-0.07 (-0.14 to 0.01)	15	-0.03 (-0.06 to 0.00)	15
Solifenacin 10mg	Treatment discontinuation	Chu, 2009[264]	70/340	58/332	0.04 (-0.04 to 0.12)	13.71	0.03 (-0.03 to 0.10)	13.71
Solifenacin	Treatment discontinuation	Pooled	252/2758	244/2345	-0.03 (-0.05 to 0.00)	100	-0.01 (-0.03 to 0.00)	100
Solifenacin	Treatment discontinuation	Heterogeneity			p value 0.401	4.10%	I-squared	4.10%
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	9/279	10/267	-0.01 (-0.10 to 0.07)	7.4	-0.01 (-0.03 to 0.03)	7.4
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	14/314	40/781	-0.03 (-0.12 to 0.05)	7.31	-0.01 (-0.04 to 0.03)	7.31

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Staskin, 2006[37]	4/159	19/430	-0.02 (-0.08 to 0.05)	10.16	-0.01 (-0.03 to 0.02)	10.16
Solifenacin 5mg	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	20/400	11/406	0.03 (-0.02 to 0.08)	13.5	0.01 (-0.01 to 0.03)	13.5
Solifenacin 7.5mg	Treatment discontinuation due to adverse effects	Cardozo, 2008[60]	15/641	4/224	-0.04 (-0.13 to 0.05)	6.59	-0.01 (-0.02 to 0.01)	6.59
Solifenacin 7.5mg	Treatment discontinuation due to adverse effects	Karram, 2009[320]	24/372	17/367	0.05 (-0.01 to 0.12)	10.07	0.02 (-0.01 to 0.06)	10.07
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	7/269	10/267	0.06 (-0.01 to 0.13)	9.54	0.03 (0.00 to 0.06)	9.54
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	51/778	40/781	0.10 (0.03 to 0.17)	9.43	0.05 (0.01 to 0.10)	9.43
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Staskin, 2006[37]	31/452	19/430	0.02 (-0.06 to 0.10)	8.44	0.01 (-0.02 to 0.05)	8.44
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	26/385	11/406	0.04 (-0.03 to 0.11)	9.04	0.02 (-0.01 to 0.05)	9.04
Solifenacin 10mg	Treatment discontinuation due to adverse effects	Chu, 2009[264]	37/340	18/332	0.10 (0.03 to 0.18)	8.51	0.05 (0.01 to 0.11)	8.51

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Pooled	237/4389	198/4691	0.03 (0.00 to 0.06)	100	0.01 (0.00 to 0.03)	100
Solifenacin	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.095	38.10%	I-squared	38.10%
Solifenacin 7.5mg	Treatment discontinuation due to failure	Cardozo, 2008[60]	11/641	6/224	-0.03 (-0.11 to 0.06)	20.53	-0.01 (-0.02 to 0.02)	20.53
Solifenacin 7.5mg	Treatment discontinuation due to failure	Toglia, 2009[321]	8/372	5/367	-0.03 (-0.11 to 0.04)	25.43	-0.01 (-0.01 to 0.01)	25.43
Solifenacin 10mg	Treatment discontinuation due to failure	Chapple, 2004[52]	1/269	2/267	0.03 (-0.04 to 0.10)	28.3	0.01 (-0.01 to 0.03)	28.3
Solifenacin 10mg	Treatment discontinuation due to failure	Chu, 2009264	4/340	3/332	0.01 (-0.06 to 0.09)	25.74	0.00 (-0.01 to 0.02)	25.74
Solifenacin	Treatment discontinuation due to failure	Pooled	24/1622	16/1190	0.00 (-0.04 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Solifenacin	Treatment discontinuation due to failure	Heterogeneity			p value 0.601	0.00%	I-squared	0.00%
Solifenacin 7.5mg	Dizziness	Karram, 2009[320]	12/372	7/367	0.04 (-0.03 to 0.11)	52.38	0.01 (-0.01 to 0.04)	52.38
Solifenacin 10mg	Dizziness	Chu, 2009[264]	10/340	8/332	0.02 (-0.06 to 0.09)	47.62	0.01 (-0.01 to 0.04)	47.62
Solifenacin	Dizziness	Pooled	22/712	15/699	0.03 (-0.02 to 0.08)	100	0.01 (-0.01 to 0.03)	100
Solifenacin	Dizziness	Heterogeneity			p value 0.638	0.00%	I-squared	0.00%
Tolterodine 2mg	Abdominal pain	Jackquetin, 2001[312]	6/97	2/51	0.07 (0.01 to 0.13)	24.53	0.03 (0.00 to 0.07)	24.53

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Abdominal pain	Van Kerrebroeck, 2001[331]	19/507	8/508	0.03 (-0.03 to 0.10)	24.69	0.01 (-0.01 to 0.03)	24.69
Tolterodine 4mg	Abdominal pain	Van Kerrebroeck, 2001[331]	13/514	8/508	0.03 (-0.13 to 0.19)	3.64	0.01 (-0.02 to 0.08)	3.64
Tolterodine 4mg	Abdominal pain	Malone-Lee, 2001[346]	6/73	5/74	0.05 (-0.12 to 0.22)	3.31	0.03 (-0.05 to 0.15)	3.31
Tolterodine 4mg	Abdominal pain	Jackquetin, 2001[312]	4/103	2/51	0.00 (-0.17 to 0.17)	3.38	0.00 (-0.04 to 0.09)	3.38
Tolterodine 4mg	Abdominal pain	Khullar, 2004[325]	12/569	2/285	0.06 (-0.01 to 0.13)	18.49	0.01 (0.00 to 0.04)	18.49
Tolterodine 4mg	Abdominal pain	NCT00444925[56]	4/690	4/337	-0.03 (-0.10 to 0.03)	21.95	-0.01 (-0.01 to 0.01)	21.95
Tolterodine	Abdominal pain	Pooled	64/2553	31/1814	0.03 (0.00 to 0.06)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Abdominal pain	Heterogeneity			p value 0.413	1.60%	I-squared	1.60%
Tolterodine 2mg	Treatment discontinuation due to adverse effects	Jackquetin, 2001[312]	3/97	1/51	-0.33 (-0.62 to -0.03)	2.18	0.01 (0.20 to -0.01)	2.18
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Abrams, 1998[219]	10/118	7/57	-0.06 (-0.22 to 0.10)	6.16	-0.04 (-0.10 to 0.07)	6.16
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Drutz, 1999[279]	7/109	4/56	-0.01 (-0.18 to 0.15)	5.99	-0.01 (-0.06 to 0.09)	5.99
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Malone-Lee, 2001[346]	7/73	1/74	0.18 (0.02 to 0.34)	5.96	0.08 (0.01 to 0.20)	5.96
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Jackquetin, 2001[312]	2/103	1/51	0.04 (-0.13 to 0.21)	5.56	0.01 (-0.02 to 0.10)	5.56

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	5/266	10/267	0.00 (-0.17 to 0.17)	5.65	0.00 (-0.04 to 0.09)	5.65
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Khullar, 2004[325]	26/569	16/285	-0.06 (-0.14 to 0.03)	12.68	-0.02 (-0.05 to 0.01)	12.68
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Chapple, 2007[253]	9/290	6/285	-0.02 (-0.09 to 0.05)	14.53	-0.01 (-0.02 to 0.02)	14.53
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Herschorn, 2008[301]	12/410	2/207	0.03 (-0.05 to 0.11)	13.09	0.01 (-0.01 to 0.03)	13.09
Tolterodine 4mg	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	28/684	6/334	0.07 (-0.01 to 0.16)	12.85	0.02 (0.00 to 0.06)	12.85
Tolterodine 7.5mg	Treatment discontinuation due to adverse effects	Rentzhog, 1998[360]	2/67	3/13	0.07 (0.00 to 0.14)	15.35	0.06 (0.00 to 0.12)	15.35
Tolterodine	Treatment discontinuation due to adverse effects	Pooled	111/2786	57/1680	0.01 (-0.03 to 0.06)	100	0.01 (-0.01 to 0.03)	100
Tolterodine	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.044	46.60%	I-squared	46.60%
Tolterodine 4mg	Treatment discontinuation due to failure	Khullar, 2004[325]	3/569	2/285	0.02 (-0.07 to 0.11)	16.45	0.00 (-0.01 to 0.03)	16.45

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Treatment discontinuation due to failure	Herschorn, 2008[301]	3/410	9/207	-0.01 (-0.08 to 0.06)	20.76	-0.01 (-0.03 to 0.03)	20.76
Tolterodine 4mg	Treatment discontinuation due to failure	Herschorn, 2010[470]	5/684	5/334	-0.12 (-0.21 to -0.04)	16.81	-0.01 (-0.01 to -0.01)	16.81
Tolterodine 4mg	Treatment discontinuation due to failure	NCT00444925[56]	5/690	5/337	-0.04 (-0.10 to 0.03)	22.93	-0.01 (-0.01 to 0.01)	22.93
Tolterodine 10mg	Treatment discontinuation due to failure	Chapple, 2004[52]	3/266	2/267	-0.04 (-0.10 to 0.03)	23.05	-0.01 (-0.01 to 0.01)	23.05
Tolterodine	Treatment discontinuation due to failure	Pooled	19/2619	23/1430	-0.04 (-0.08 to 0.00)	100	-0.01 (-0.01 to 0.00)	100
Tolterodine	Treatment discontinuation due to failure	Heterogeneity			p value 0.174	37.10%	I-squared	37.10%
Tolterodine 4mg	Dizziness	Van Kerrebroeck, 2001[331]	11/507	5/508	0.05 (-0.01 to 0.11)	19.93	0.01 (0.00 to 0.03)	19.93
Tolterodine 4mg	Dizziness	Van Kerrebroeck, 2001[331]	9/514	5/508	0.03 (-0.03 to 0.10)	20.05	0.01 (0.00 to 0.03)	20.05
Tolterodine 4mg	Dizziness	Malone-Lee, 2001[346]	4/73	7/74	-0.08 (-0.24 to 0.09)	3.23	-0.04 (-0.09 to 0.06)	3.23
Tolterodine 4mg	Dizziness	Khullar, 2004[325]	6/569	3/285	0.00 (-0.07 to 0.07)	15.39	0.00 (-0.01 to 0.02)	15.39
Tolterodine 4mg	Dizziness	Chapple, 2007[253]	4/290	7/285	-0.04 (-0.12 to 0.04)	11.93	-0.01 (-0.02 to 0.01)	11.93
Tolterodine 4mg	Dizziness	Herschorn, 200[8301]	5/410	5/207	-0.05 (-0.13 to 0.04)	11.45	-0.01 (-0.02 to 0.01)	11.45
Tolterodine 4mg	Dizziness	NCT00444925[56]	10/690	3/337	0.03 (-0.04 to 0.09)	18.02	0.01 (-0.01 to 0.03)	18.02
Tolterodine	Dizziness	Pooled	49/3053	35/2204	0.01 (-0.02 to 0.04)	100	0.00 (0.00 to 0.01)	100
Tolterodine	Dizziness	Heterogeneity			p value 0.362	8.70%	I-squared	8.70%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 1mg	Dry mouth	Rentzhog, 1998[360]	2/21	2/13	-0.09 (-0.44 to 0.26)	1.46	-0.06 (-0.15 to 0.22)	1.46
Tolterodine 2mg	Dry mouth	Rentzhog, 1998[360]	2/16	2/13	-0.04 (-0.41 to 0.32)	1.32	-0.03 (-0.15 to 0.29)	1.32
Tolterodine 4mg	Dry mouth	Rentzhog, 1998[360]	5/14	2/13	0.24 (-0.14 to 0.62)	1.25	0.20 (-0.09 to 0.57)	1.25
Tolterodine 4mg	Dry mouth	Abrams, 1998[219]	59/118	12/57	0.45 (0.08 to 0.81)	1.32	0.42 (0.07 to 0.71)	1.32
Tolterodine 4mg	Dry mouth	Van Kerrebroeck, 2001[331]	118/507	39/508	0.31 (0.15 to 0.47)	4.76	0.23 (0.10 to 0.39)	4.76
Tolterodine 4mg	Dry mouth	Jackquetin, 2001[312]	35/103	3/51	0.22 (0.16 to 0.28)	9.61	0.14 (0.10 to 0.20)	9.61
Tolterodine 4mg	Dry mouth	Chapple, 2004[260]	9/37	0/38	0.38 (0.21 to 0.55)	4.42	0.14 (0.04 to 0.27)	4.42
Tolterodine 4mg	Dry mouth	Chapple, 2007[253]	49/290	20/285	0.52 (0.29 to 0.74)	2.93	0.43 (0.21 to 0.65)	2.93
Tolterodine 4mg	Dry mouth	Rogers, 2008[365]	26/202	19/211	0.22 (0.14 to 0.31)	8.25	0.16 (0.09 to 0.24)	8.25
Tolterodine 4mg	Dry mouth	Herschorn, 2008[301]	89/410	21/207	0.16 (0.07 to 0.24)	8.43	0.11 (0.05 to 0.18)	8.43
Tolterodine 4mg	Dry mouth	Malone-Lee, 2009[345]	20/165	0/142	0.06 (-0.03 to 0.16)	7.59	0.00 (0.00 to 0.03)	7.59
Tolterodine 4mg	Dry mouth	Herschorn, 2010[470]	112/684	20/334	0.16 (0.08 to 0.24)	8.33	0.10 (0.04 to 0.16)	8.33
Tolterodine 4mg	Dry mouth	Junemann, 2000[316]	21/76	5/79	0.35 (0.24 to 0.47)	6.75	0.26 (0.16 to 0.37)	6.75
Tolterodine 4mg	Dry mouth	Kaplan, 2010[318]	127/974	24/480	0.17 (0.10 to 0.24)	9.39	0.10 (0.05 to 0.15)	9.39
Tolterodine 4mg	Dry mouth	NCT00444925[56]	112/690	20/337	0.30 (0.14 to 0.46)	4.78	0.21 (0.08 to 0.36)	4.78
Tolterodine 8mg	Dry mouth	Rentzhog, 1998[360]	9/16	2/13	0.14 (0.09 to 0.20)	10	0.12 (0.07 to 0.17)	10
Tolterodine 10mg	Dry mouth	Chapple, 2004[52]	49/266	13/267	0.17 (0.10 to 0.23)	9.4	0.10 (0.05 to 0.15)	9.4
Tolterodine	Dry mouth	Pooled	844/4589	204/3048	0.21 (0.16 to 0.25)	100	0.14 (0.10 to 0.18)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine	Dry mouth	Heterogeneity			p value 0	63.60%	I-squared	63.60%
Tolterodine 4mg	Dyspepsia	Abrams, 1998[219]	11/118	3/57	0.08 (-0.08 to 0.24)	10.84	0.04 (-0.03 to 0.15)	10.84
Tolterodine 4mg	Dyspepsia	Van Kerrebroeck, 2001[331]	15/507	7/508	0.06 (-0.01 to 0.12)	21.66	0.02 (0.00 to 0.04)	21.66
Tolterodine 4mg	Dyspepsia	Malone-Lee, 2001[346]	6/73	9/74	-0.07 (-0.23 to 0.10)	10.55	-0.04 (-0.11 to 0.07)	10.55
Tolterodine 4mg	Dyspepsia	Khullar, 2004[325]	7/569	2/285	0.03 (-0.04 to 0.10)	20.43	0.01 (-0.01 to 0.03)	20.43
Tolterodine 4mg	Dyspepsia	Malone-Lee, 2009[345]	12/165	0/142	0.27 (0.16 to 0.38)	15.31	0.07 (0.02 to 0.14)	15.31
Tolterodine 4mg	Dyspepsia	NCT00444925[56]	8/690	1/337	0.05 (-0.01 to 0.12)	21.2	0.01 (0.00 to 0.03)	21.2
Tolterodine	Dyspepsia	Pooled	59/2122	22/1403	0.07 (0.00 to 0.14)	100	0.02 (0.00 to 0.05)	100
Tolterodine	Dyspepsia	Heterogeneity			p value 0.006	69.50%	I-squared	69.50%
Tolterodine 4mg	Treatment failure	Freeman, 2003[286]	88/398	168/374	-0.25 (-0.32 to -0.17)	17.28	-0.23 (-0.28 to -0.17)	17.28
Tolterodine 4mg	Treatment failure	Rogers, 2008[365]	0/202	1/211	-0.07 (-0.17 to 0.03)	15.54	0.00 (0.00 to 0.00)	15.54
Tolterodine 4mg	Treatment failure	Herschorn, 2008[301]	16/410	19/207	-0.10 (-0.19 to -0.02)	16.43	-0.05 (-0.08 to -0.01)	16.43
Tolterodine 4mg	Treatment failure	Rogers, 2009[364]	16/202	12/211	0.04 (-0.05 to 0.14)	15.54	0.02 (-0.02 to 0.08)	15.54
Tolterodine 4mg	Treatment failure	Herschorn, 2010[470]	64/684	34/334	-0.02 (-0.08 to 0.05)	17.6	-0.01 (-0.04 to 0.03)	17.6
Tolterodine 4mg	Treatment failure	NCT00444925[56]	59/690	36/337	-0.04 (-0.10 to 0.03)	17.62	-0.02 (-0.05 to 0.02)	17.62
Tolterodine	Treatment failure	Pooled	244/2586	270/1674	-0.07 (-0.15 to 0.01)	100	-0.05 (-0.10 to 0.01)	100
Tolterodine	Treatment failure	Heterogeneity			p value 0	84.90%	I-squared	84.90%
Tolterodine 4mg	Fatigue	Van Kerrebroeck, 2001[331]	11/507	4/508	0.06 (0.00 to 0.12)	32.85	0.01 (0.00 to 0.04)	32.85
Tolterodine 4mg	Fatigue	Chapple, 2007[253]	10/290	1/285	0.13 (0.05 to 0.21)	19.2	0.03 (0.01 to 0.07)	19.2

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Fatigue	Herschorn, 2008[301]	11/410	4/207	0.03 (-0.06 to 0.11)	18.41	0.01 (-0.01 to 0.04)	18.41
Tolterodine 4mg	Fatigue	NCT00444925[56]	4/690	0/337	0.08 (0.01 to 0.14)	29.54	0.01 (0.00 to 0.02)	29.54
Tolterodine	Fatigue	Pooled	36/1897	9/1337	0.07 (0.03 to 0.11)	100	0.02 (0.01 to 0.03)	100
Tolterodine	Fatigue	Heterogeneity			p value 0.366	5.30%	I-squared	5.30%
Tolterodine 1mg	Abnormal vision	Rentzhog, 1998[360]	0/21	1/13	-0.28 (-0.63 to 0.07)	2.82	-0.08 (0.04 to 0.04)	2.82
Tolterodine 2mg	Abnormal vision	Rentzhog, 1998[360]	3/16	1/13	0.17 (-0.20 to 0.53)	2.52	0.11 (-0.07 to 0.45)	2.52
Tolterodine 4mg	Abnormal vision	Rentzhog, 1998[360]	1/14	1/13	-0.01 (-0.39 to 0.37)	2.37	-0.01 (-0.07 to 0.29)	2.37
Tolterodine 4mg	Abnormal vision	Van Kerrebroeck, 2001[331]	4/514	2/508	-0.03 (-0.39 to 0.34)	2.52	0.00 (0.10 to 0.15)	2.52
Tolterodine 8mg	Abnormal vision	Rentzhog, 1998[360]	1/16	1/13	0.03 (-0.04 to 0.09)	89.77	0.01 (-0.02 to 0.05)	89.77
Tolterodine	Abnormal vision	Pooled	9/581	6/560	0.02 (-0.04 to 0.08)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Abnormal vision	Heterogeneity			p value 0.456	0.00%	I-squared	0.00%
Tolterodine 2mg	General body disorders	Jonas, 1997[314]	6/99	4/44	-0.06 (-0.24 to 0.12)	47.67	-0.03 (-0.09 to 0.08)	47.67
Tolterodine 4mg	General body disorders	Drutz, 1999[279]	40/109	15/56	0.12 (-0.04 to 0.28)	52.33	0.11 (-0.04 to 0.27)	52.33
Tolterodine	General body disorders	Pooled	46/208	19/100	0.04 (-0.14 to 0.21)	100	0.03 (-0.09 to 0.18)	100
Tolterodine	General body disorders	Heterogeneity			p value 0.149	51.90%	I-squared	51.90%
Tolterodine 2mg	Headache	Jonas, 1997[314]	3/99	1/44	0.02 (-0.15 to 0.20)	3.73	0.01 (-0.02 to 0.10)	3.73
Tolterodine 2mg	Headache	Malone-Lee, 2001[346]	5/61	2/74	0.02 (-0.15 to 0.20)	3.73	0.01 (-0.03 to 0.10)	3.73
Tolterodine 2mg	Headache	Jackquetin, 2001[312]	3/97	2/51	0.04 (-0.02 to 0.10)	10.66	0.02 (-0.01 to 0.05)	10.66
Tolterodine 4mg	Headache	Jonas, 1997[314]	3/99	1/44	-0.02 (-0.08 to 0.04)	10.68	-0.01 (-0.02 to 0.01)	10.68

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Headache	Van Kerrebroeck, 2001[331]	32/507	23/508	0.13 (-0.04 to 0.30)	3.99	0.07 (-0.02 to 0.19)	3.99
Tolterodine 4mg	Headache	Van Kerrebroeck, 2001[331]	19/514	23/508	0.15 (-0.01 to 0.31)	4.27	0.08 (0.00 to 0.21)	4.27
Tolterodine 4mg	Headache	Malone-Lee, 2001[346]	7/73	2/74	-0.02 (-0.19 to 0.15)	3.99	-0.01 (-0.03 to 0.07)	3.99
Tolterodine 4mg	Headache	Jackquetin, 2001[312]	3/103	2/51	-0.03 (-0.20 to 0.14)	4.05	-0.01 (-0.04 to 0.07)	4.05
Tolterodine 4mg	Headache	Chapple, 2004[260]	0/37	1/38	-0.16 (-0.39 to 0.06)	2.55	-0.03 (0.02 to 0.02)	2.55
Tolterodine 4mg	Headache	Khullar, 2004[325]	22/569	8/285	0.03 (-0.04 to 0.10)	9.83	0.01 (-0.01 to 0.04)	9.83
Tolterodine 4mg	Headache	Chapple, 2007[253]	14/290	14/285	0.00 (-0.08 to 0.08)	8.93	0.00 (-0.03 to 0.04)	8.93
Tolterodine 4mg	Headache	Rogers, 2008[365]	7/202	6/211	0.02 (-0.08 to 0.11)	7.78	0.01 (-0.02 to 0.05)	7.78
Tolterodine 4mg	Headache	Herschorn, 2008[301]	21/410	9/207	0.02 (-0.07 to 0.10)	8.78	0.01 (-0.02 to 0.05)	8.78
Tolterodine 4mg	Headache	Malone-Lee, 2009[345]	13/165	0/142	0.29 (0.18 to 0.40)	6.71	0.08 (0.03 to 0.15)	6.71
Tolterodine 4mg	Headache	Herschorn, 2010[470]	23/684	8/334	0.03 (-0.04 to 0.10)	10.32	0.01 (-0.01 to 0.04)	10.32
Tolterodine	Headache	Pooled	175/3910	102/2856	0.04 (0.00 to 0.08)	100	0.01 (0.00 to 0.03)	100
Tolterodine	Headache	Heterogeneity			p value 0.006	54.20%	I-squared	54.20%
Tolterodine 4mg	Insomnia	Van Kerrebroeck, 2001331	7/507	9/508	-0.02 (-0.08 to 0.05)	52.38	0.00 (-0.01 to 0.01)	52.38
Tolterodine 4mg	Insomnia	Rogers, 2008[365]	5/202	0/211	0.16 (0.06 to 0.25)	47.62	0.02 (0.00 to 0.06)	47.62
Tolterodine	Insomnia	Pooled	12/709	9/719	0.07 (-0.10 to 0.24)	100	0.02 (-0.01 to 0.10)	100
Tolterodine	Insomnia	Heterogeneity			p value 0.003	88.70%	I-squared	88.70%
Tolterodine 4mg	Nasopharyngitis	Chapple, 2007[253]	10/290	7/285	0.03 (-0.05 to 0.11)	21.25	0.01 (-0.01 to 0.05)	21.25
Tolterodine 4mg	Nasopharyngitis	Chapple, 2008[254]	10/290	7/283	0.03 (-0.05 to 0.11)	21.18	0.01 (-0.01 to 0.05)	21.18

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Nasopharyngitis	Rogers, 2008[365]	9/202	10/211	-0.01 (-0.10 to 0.09)	15.26	0.00 (-0.03 to 0.05)	15.26
Tolterodine 4mg	Nasopharyngitis	Herschorn, 2008[301]	9/410	5/207	-0.01 (-0.09 to 0.08)	20.34	0.00 (-0.02 to 0.03)	20.34
Tolterodine 4mg	Nasopharyngitis	Sand, 2009[370]	8/227	12/430	0.02 (-0.06 to 0.10)	21.97	0.01 (-0.02 to 0.04)	21.97
Tolterodine	Nasopharyngitis	Pooled	46/1419	41/1416	0.01 (-0.02 to 0.05)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Nasopharyngitis	Heterogeneity			p value 0.949	0.00%	I-squared	0.00%
Tolterodine 4mg	Nausea	Abrams, 1998[219]	4/118	6/57	-0.15 (-0.30 to 0.01)	5.01	-0.07 (-0.10 to 0.01)	5.01
Tolterodine 4mg	Nausea	Van Kerrebroeck, 2001[331]	7/507	10/508	-0.02 (-0.09 to 0.04)	20.04	-0.01 (-0.02 to 0.01)	20.04
Tolterodine 4mg	Nausea	Van Kerrebroeck, 2001[331]	10/514	10/508	0.00 (-0.06 to 0.06)	20.12	0.00 (-0.01 to 0.02)	20.12
Tolterodine 4mg	Nausea	Malone-Lee, 2001[346]	3/73	2/74	0.04 (-0.12 to 0.20)	4.81	0.01 (-0.03 to 0.10)	4.81
Tolterodine 4mg	Nausea	Khullar, 2004[325]	7/569	5/285	-0.02 (-0.09 to 0.05)	16.98	-0.01 (-0.02 to 0.02)	16.98
Tolterodine 4mg	Nausea	Chapple, 2007[253]	6/290	1/285	0.09 (0.00 to 0.17)	14.21	0.02 (0.00 to 0.05)	14.21
Tolterodine 4mg	Nausea	NCT00444925[56]	7/690	6/337	-0.03 (-0.10 to 0.03)	18.83	-0.01 (-0.02 to 0.01)	18.83
Tolterodine	Nausea	Pooled	44/2761	40/2054	-0.01 (-0.05 to 0.03)	100	0.00 (-0.01 to 0.01)	100
Tolterodine	Nausea	Heterogeneity			p value 0.163	34.70%	I-squared	34.70%
Tolterodine 2mg	Serious adverse effects	Millard, 1999[349]	5/129	1/64	0.07 (-0.08 to 0.22)	5.25	0.02 (-0.01 to 0.10)	5.25
Tolterodine 2mg	Serious adverse effects	Van Kerrebroeck, 2001[331]	12/507	18/508	-0.09 (-0.26 to 0.07)	4.54	-0.03 (-0.03 to 0.03)	4.54
Tolterodine 2mg	Serious adverse effects	Malone-Lee, 2001[346]	2/61	1/74	-0.04 (-0.10 to 0.03)	29.72	-0.01 (-0.01 to 0.01)	29.72
Tolterodine 4mg	Serious adverse effects	Drutz, 1999[279]	1/109	2/56	-0.07 (-0.13 to -0.01)	29.72	-0.02 (-0.03 to 0.00)	29.72
Tolterodine 4mg	Serious adverse effects	Van Kerrebroeck, 2001[331]	7/507	18/508	0.07 (-0.10 to 0.24)	4.11	0.03 (-0.03 to 0.13)	4.11

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Serious adverse effects	NCT00444925[56]	9/690	8/337	-0.04 (-0.11 to 0.03)	26.67	-0.01 (-0.02 to 0.01)	26.67
Tolterodine	Serious adverse effects	Pooled	36/2003	48/1547	-0.04 (-0.08 to -0.01)	100	-0.01 (-0.02 to 0.00)	100
Tolterodine	Serious adverse effects	Heterogeneity			p value 0.399	2.80%	I-squared	2.80%
Tolterodine 4mg	Somnolence	Van Kerrebroeck, 2001[331]	14/507	9/508	0.03 (-0.03 to 0.10)	52.92	0.01 (-0.01 to 0.03)	52.92
Tolterodine 4mg	Somnolence	Khullar, 2004[325]	1/569	2/285	-0.04 (-0.11 to 0.03)	47.08	-0.01 (-0.01 to 0.01)	47.08
Tolterodine	Somnolence	Pooled	15/1076	11/793	0.00 (-0.08 to 0.07)	100	0.00 (-0.01 to 0.02)	100
Tolterodine	Somnolence	Heterogeneity			p value 0.116	59.50%	I-squared	59.50%
Tolterodine 4mg	Urinary tract infection	Jonas, 1997[314]	2/99	2/44	-0.07 (-0.25 to 0.11)	4.74	-0.03 (-0.04 to 0.05)	4.74
Tolterodine 4mg	Urinary tract infection	Van Kerrebroeck, 2001[331]	16/507	20/508	-0.02 (-0.08 to 0.04)	21.72	-0.01 (-0.03 to 0.02)	21.72
Tolterodine 4mg	Urinary tract infection	Van Kerrebroeck, 2001[331]	13/514	20/508	-0.04 (-0.10 to 0.02)	21.8	-0.01 (-0.03 to 0.01)	21.8
Tolterodine 4mg	Urinary tract infection	Khullar, 2004[325]	2/569	2/285	-0.03 (-0.10 to 0.05)	18.65	0.00 (-0.01 to 0.01)	18.65
Tolterodine 4mg	Urinary tract infection	Rogers, 2008[365]	12/202	5/211	0.09 (-0.01 to 0.19)	12.67	0.04 (0.00 to 0.09)	12.67
Tolterodine 4mg	Urinary tract infection	Herschorn, 2010[470]	10/684	2/334	0.05 (-0.02 to 0.11)	20.42	0.01 (0.00 to 0.03)	20.42
Tolterodine	Urinary tract infection	Pooled	55/2575	51/1890	0.00 (-0.04 to 0.04)	100	0.00 (-0.01 to 0.01)	100
Tolterodine	Urinary tract infection	Heterogeneity			p value 0.133	40.90%	I-squared	40.90%
Tolterodine 1mg	Adverse effects	Rentzhog, 1998[360]	8/21	6/13	-0.08 (-0.25 to 0.10)	3.86	-0.08 (-0.24 to 0.10)	3.86
Tolterodine 2mg	Adverse effects	Jonas, 1997[314]	31/99	17/44	-0.06 (-0.44 to 0.32)	0.91	-0.06 (-0.33 to 0.31)	0.91
Tolterodine 2mg	Adverse effects	Rentzhog, 1998[360]	6/16	6/13	-0.08 (-0.43 to 0.26)	1.07	-0.08 (-0.36 to 0.26)	1.07

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Adverse effects	Rentzhog, 1998[360]	10/14	10/13	-0.09 (-0.45 to 0.28)	0.96	-0.08 (-0.44 to 0.18)	0.96
Tolterodine 4mg	Adverse effects	Abrams, 1998[219]	105/118	46/57	0.30 (-0.07 to 0.67)	0.96	0.17 (-0.05 to 0.15)	0.96
Tolterodine 4mg	Adverse effects	Drutz, 1999[279]	85/109	42/56	0.12 (-0.04 to 0.28)	4.78	0.09 (-0.04 to 0.19)	4.78
Tolterodine 4mg	Adverse effects	Jackquetin, 2001[312]	55/103	16/51	0.04 (-0.13 to 0.20)	4.62	0.03 (-0.11 to 0.19)	4.62
Tolterodine 4mg	Adverse effects	Chapple, 2004[260]	12/37	6/38	0.23 (0.06 to 0.39)	4.29	0.19 (0.04 to 0.36)	4.29
Tolterodine 4mg	Adverse effects	Khullar, 2004[325]	221/569	96/285	0.20 (-0.03 to 0.42)	2.44	0.19 (-0.03 to 0.41)	2.44
Tolterodine 4mg	Adverse effects	Chapple, 2007[253]	144/290	107/285	0.05 (-0.02 to 0.13)	17.46	0.05 (-0.02 to 0.12)	17.46
Tolterodine 4mg	Adverse effects	Rogers, 2008[365]	114/202	111/211	0.12 (0.04 to 0.20)	14.36	0.12 (0.04 to 0.20)	14.36
Tolterodine 4mg	Adverse effects	Malone-Lee, 2009[345]	88/165	67/142	0.04 (-0.06 to 0.14)	11.15	0.04 (-0.06 to 0.13)	11.15
Tolterodine 4mg	Adverse effects	Junemann, 2000[316]	25/76	12/79	0.06 (-0.05 to 0.17)	8.72	0.05 (-0.03 to 0.14)	8.72
Tolterodine 4mg	Adverse effects	NCT00444925[56]	213/690	76/337	0.21 (0.05 to 0.37)	4.81	0.19 (0.05 to 0.35)	4.81
Tolterodine 8mg	Adverse effects	Rentzhog, 1998[360]	12/16	6/13	0.09 (0.03 to 0.16)	19.59	0.09 (0.03 to 0.16)	19.59
Tolterodine	Adverse effects	Pooled	1129/2525	624/1637	0.08 (0.05 to 0.12)	100	0.08 (0.05 to 0.12)	100
Tolterodine	Adverse effects	Heterogeneity			p value 0.306	13.20%	I-squared	13.20%
Tolterodine 2mg	Autonomic nervous system	Jonas, 1997[314]	11/99	4/44	0.11 (-0.07 to 0.29)	17.49	0.07 (-0.04 to 0.22)	17.49
Tolterodine 2mg	Autonomic nervous system	Millard, 1999[349]	37/129	11/64	0.03 (-0.14 to 0.21)	17.49	0.03 (-0.09 to 0.18)	17.49
Tolterodine 4mg	Autonomic nervous system	Jonas, 1997[314]	16/99	4/44	0.14 (-0.01 to 0.29)	22.51	0.10 (0.00 to 0.23)	22.51
Tolterodine 4mg	Autonomic nervous system	Millard, 1999[349]	53/123	11/64	0.29 (0.14 to 0.44)	22.26	0.26 (0.12 to 0.41)	22.26

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Autonomic nervous system	Drutz, 1999[279]	35/109	12/56	0.11 (-0.05 to 0.27)	20.26	0.10 (-0.04 to 0.26)	20.26
Tolterodine	Autonomic nervous system	Pooled	152/559	42/272	0.14 (0.06 to 0.23)	100	0.12 (0.05 to 0.20)	100
Tolterodine	Autonomic nervous system	Heterogeneity			p value 0.25	25.70%	I-squared	25.70%
Tolterodine 4mg	Back pain	Herschorn, 2008[301]	8/410	2/207	0.04 (-0.04 to 0.13)	47.25	0.01 (-0.01 to 0.04)	47.25
Tolterodine 4mg	Back pain	NCT00444925[56]	7/690	10/337	-0.07 (-0.14 to -0.01)	52.75	-0.02 (-0.03 to 0.00)	52.75
Tolterodine	Back pain	Pooled	15/1100	12/544	-0.02 (-0.13 to 0.09)	100	0.00 (-0.02 to 0.04)	100
Tolterodine	Back pain	Heterogeneity			p value 0.035	77.50%	I-squared	77.50%
Tolterodine 4mg	Blurred vision	Chapple, 2004[260]	0/37	2/38	-0.23 (-0.46 to -0.01)	34.42	-0.05 (0.00 to 0.00)	34.42
Tolterodine 10mg	Blurred vision	Chapple, 2004[52]	4/266	7/267	-0.04 (-0.13 to 0.05)	65.58	-0.01 (-0.02 to 0.02)	65.58
Tolterodine	Blurred vision	Pooled	4/303	9/305	-0.11 (-0.28 to 0.07)	100	-0.03 (-0.02 to 0.03)	100
Tolterodine	Blurred vision	Heterogeneity			p value 0.12	58.60%	I-squared	58.60%
Tolterodine 1mg	Constipation	Rentzhog, 1998[360]	1/21	0/13	-0.07 (-0.25 to 0.11)	1.73	0.01 (0.06 to 0.01)	1.73
Tolterodine 2mg	Constipation	Jonas, 1997[314]	2/99	2/44	-0.04 (-0.22 to 0.14)	1.73	-0.02 (-0.05 to 0.07)	1.73
Tolterodine 2mg	Constipation	Rentzhog, 1998[360]	3/16	0/13	0.22 (-0.13 to 0.57)	0.47	0.05 (0.02 to 0.29)	0.47
Tolterodine 2mg	Constipation	Malone-Lee, 2001[346]	5/61	2/74	0.45 (0.08 to 0.81)	0.42	0.30 (0.03 to 0.66)	0.42
Tolterodine 2mg	Constipation	Jackquetin, 2001[312]	4/97	2/51	0.27 (-0.11 to 0.65)	0.4	0.17 (-0.03 to 0.52)	0.4
Tolterodine 4mg	Constipation	Jonas, 1997[314]	3/99	2/44	0.36 (-0.01 to 0.73)	0.42	0.25 (0.00 to 0.61)	0.42
Tolterodine 4mg	Constipation	Rentzhog, 1998[360]	1/14	0/13	0.04 (-0.03 to 0.10)	10.44	0.00 (0.00 to 0.01)	10.44
Tolterodine 4mg	Constipation	Van Kerrebroeck, 2001[331]	30/507	22/508	0.05 (-0.01 to 0.12)	10.49	0.02 (0.00 to 0.06)	10.49

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Constipation	Van Kerrebroeck, 2001[331]	35/514	22/508	0.13 (-0.04 to 0.30)	1.89	0.06 (-0.02 to 0.19)	1.89
Tolterodine 4mg	Constipation	Malone-Lee, 2001[346]	0/73	2/74	-0.17 (-0.33 to 0.00)	2.07	-0.03 (0.00 to 0.00)	2.07
Tolterodine 4mg	Constipation	Jackquetin, 2001[312]	2/103	2/51	0.01 (-0.16 to 0.18)	1.89	0.00 (-0.04 to 0.09)	1.89
Tolterodine 4mg	Constipation	Chapple, 2004[260]	1/37	0/38	-0.06 (-0.23 to 0.11)	1.93	0.00 (0.05 to 0.01)	1.93
Tolterodine 4mg	Constipation	Khullar, 2004[325]	9/569	2/285	0.17 (-0.06 to 0.39)	1.09	0.05 (-0.01 to 0.20)	1.09
Tolterodine 4mg	Constipation	Chapple, 2007[253]	8/290	4/285	0.03 (-0.06 to 0.11)	6.44	0.01 (-0.01 to 0.04)	6.44
Tolterodine 4mg	Constipation	Rogers, 2008[365]	7/202	8/211	0.04 (-0.03 to 0.11)	8.48	0.02 (-0.01 to 0.05)	8.48
Tolterodine 4mg	Constipation	Herschorn, 2008[301]	11/410	3/207	0.05 (-0.03 to 0.13)	6.84	0.01 (-0.01 to 0.05)	6.84
Tolterodine 4mg	Constipation	Herschorn, 2010[470]	28/684	10/334	-0.01 (-0.11 to 0.09)	5.22	0.00 (-0.03 to 0.04)	5.22
Tolterodine 4mg	Constipation	Kaplan, 2010[318]	29/974	10/480	0.04 (-0.04 to 0.13)	6.61	0.01 (-0.01 to 0.05)	6.61
Tolterodine 4mg	Constipation	NCT00444925[56]	28/690	10/337	0.03 (-0.04 to 0.10)	9.58	0.01 (-0.01 to 0.04)	9.58
Tolterodine 8mg	Constipation	Rentzhog, 1998[360]	2/16	0/13	0.03 (-0.02 to 0.09)	12.21	0.00 (0.00 to 0.01)	12.21
Tolterodine 10mg	Constipation	Chapple, 2004[52]	7/266	5/267	0.03 (-0.04 to 0.10)	9.64	0.01 (-0.01 to 0.03)	9.64
Tolterodine	Constipation	Pooled	216/5742	108/3850	0.03 (0.01 to 0.06)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Constipation	Heterogeneity			p value 0.258	15.50%	I-squared	15.50%
Tolterodine 4mg	Diarrhea	Van Kerrebroeck, 2001[331]	10/507	11/508	-0.01 (-0.07 to 0.06)	26.42	0.00 (-0.02 to 0.02)	26.42
Tolterodine 4mg	Diarrhea	Van Kerrebroeck, 2001[331]	16/514	11/508	0.03 (-0.03 to 0.09)	26.61	0.01 (-0.01 to 0.03)	26.61
Tolterodine 4mg	Diarrhea	Malone-Lee, 2001[346]	4/73	5/74	-0.03 (-0.19 to 0.14)	3.83	-0.01 (-0.06 to 0.08)	3.83

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Tolterodine 4mg	Diarrhea	Khullar, 2004[325]	10/569	3/285	0.03 (-0.04 to 0.10)	19.77	0.01 (-0.01 to 0.03)	19.77
Tolterodine 4mg	Diarrhea	Herschorn, 2010[470]	15/684	4/334	0.04 (-0.03 to 0.11)	23.37	0.01 (0.00 to 0.03)	23.37
Tolterodine	Diarrhea	Pooled	55/2347	34/1709	0.02 (-0.01 to 0.05)	100	0.01 (0.00 to 0.02)	100
Tolterodine	Diarrhea	Heterogeneity			p value 0.818	0.00%	I-squared	0.00%
Tolterodine 4mg	Treatment discontinuation	Drutz, 1999[279]	14/109	8/56	-0.02 (-0.18 to 0.14)	3.84	-0.01 (-0.10 to 0.11)	3.84
Tolterodine 4mg	Treatment discontinuation	Van Kerrebroeck, 2001[331]	1/507	8/508	-0.08 (-0.14 to -0.02)	18.26	-0.01 (-0.02 to 0.00)	18.26
Tolterodine 4mg	Treatment discontinuation	Chapple, 2004[260]	5/37	6/38	-0.03 (-0.26 to 0.19)	2.02	-0.02 (-0.14 to 0.16)	2.02
Tolterodine 4mg	Treatment discontinuation	DuBeau, 2005[280]	29/569	18/285	-0.02 (-0.10 to 0.07)	11.57	-0.01 (-0.04 to 0.04)	11.57
Tolterodine 4mg	Treatment discontinuation	Chapple, 2007[253]	37/290	33/285	-0.03 (-0.10 to 0.05)	15.03	-0.02 (-0.05 to 0.03)	15.03
Tolterodine 4mg	Treatment discontinuation	Robinson, 2007[363]	8/61	2/61	0.02 (-0.06 to 0.10)	12.26	0.01 (-0.02 to 0.04)	12.26
Tolterodine 4mg	Treatment discontinuation	Herschorn, 2010[470]	56/684	30/334	0.19 (0.01 to 0.37)	3.21	0.13 (0.01 to 0.30)	3.21
Tolterodine 4mg	Treatment discontinuation	NCT00444925[56]	6/690	3/337	-0.01 (-0.08 to 0.05)	16.85	0.00 (-0.01 to 0.01)	16.85
Tolterodine 10mg	Treatment discontinuation	Chapple, 2004[52]	29/266	32/267	0.00 (-0.07 to 0.06)	16.95	0.00 (-0.04 to 0.04)	16.95
Tolterodine	Treatment discontinuation	Pooled	185/3213	140/2171	-0.02 (-0.05 to 0.02)	100	-0.01 (-0.02 to 0.01)	100
Tolterodine	Treatment discontinuation	Heterogeneity			p value 0.241	22.80%	I-squared	22.80%
Trospium 60mg	Abdominal distention	Staskin, 2007[45]	3/298	1/303	0.04 (-0.04 to 0.12)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Abdominal distention	Sand, 2009[371]	6/484	2/505	0.05 (-0.01 to 0.11)	62.19	0.01 (0.00 to 0.03)	62.19
Trospium	Abdominal distention	Pooled	9/782	3/808	0.05 (0.00 to 0.10)	100	0.01 (0.00 to 0.02)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium	Abdominal distention	Heterogeneity			p value 0.914	0.00%	I-squared	0.00%
Trospium 60mg	Dry eye	Staskin, 2007[45]	4/298	1/303	0.06 (-0.02 to 0.14)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Dry eye	Sand, 2009[371]	9/484	1/505	0.09 (0.03 to 0.16)	62.19	0.02 (0.00 to 0.04)	62.19
Trospium	Dry eye	Pooled	13/782	2/808	0.08 (0.03 to 0.13)	100	0.01 (0.00 to 0.03)	100
Trospium	Dry eye	Heterogeneity			p value 0.515	0.00%	I-squared	0.00%
Trospium 40mg	Dry mouth	Zinner, 2004[35]	57/262	17/261	0.23 (0.14 to 0.31)	16.5	0.15 (0.09 to 0.23)	16.5
Trospium 40mg	Dry mouth	Rudy, 2006[367]	65/329	17/329	0.23 (0.16 to 0.31)	18.75	0.15 (0.09 to 0.21)	18.75
Trospium 40mg	Dry mouth	Junemann, 2000[316]	22/76	5/79	0.13 (0.05 to 0.21)	17.85	0.08 (0.02 to 0.13)	17.85
Trospium 60mg	Dry mouth	Staskin, 2007[45]	26/298	9/303	0.15 (0.07 to 0.23)	17.23	0.07 (0.03 to 0.13)	17.23
Trospium 60mg	Dry mouth	Dmochowski, 2008[272]	36/280	13/284	0.15 (0.09 to 0.21)	22.76	0.08 (0.04 to 0.13)	22.76
Trospium 60mg	Dry mouth	Sand, 2009[371]	55/484	19/505	0.31 (0.16 to 0.47)	6.91	0.20 (0.08 to 0.34)	6.91
Trospium	Dry mouth	Pooled	261/1729	80/1761	0.19 (0.14 to 0.23)	100	0.11 (0.07 to 0.14)	100
Trospium	Dry mouth	Heterogeneity			p value 0.116	43.30%	I-squared	43.30%
Trospium 60mg	Dry skin	Staskin, 2007[45]	3/298	0/303	0.10 (0.02 to 0.18)	37.81	0.01 (0.00 to 0.03)	37.81
Trospium 60mg	Dry skin	Sand, 2009[371]	5/484	1/505	0.06 (-0.01 to 0.12)	62.19	0.01 (0.00 to 0.02)	62.19
Trospium	Dry skin	Pooled	8/782	1/808	0.07 (0.02 to 0.12)	100	0.01 (0.00 to 0.02)	100
Trospium	Dry skin	Heterogeneity			p value 0.404	0.00%	I-squared	0.00%
					0.00 (0.00 to 0.00)		0.00 (0.00 to 0.00)	
Trospium 60mg	Dyspepsia	Staskin, 2007[45]	6/298	3/303	0.04 (-0.04 to 0.12)	37.81	0.01 (-0.01 to 0.04)	37.81

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Dyspepsia	Sand, 2009[371]	6/484	4/505	0.02 (-0.04 to 0.09)	62.19	0.00 (-0.01 to 0.02)	62.19
Trospium	Dyspepsia	Pooled	12/782	7/808	0.03 (-0.02 to 0.08)	100	0.00 (0.00 to 0.00)	100
Trospium	Dyspepsia	Heterogeneity			p value 0.695	0.00%	I-squared	0.00%
Trospium 40mg	Headache	Zinner, 2004[35]	17/262	12/261	0.04 (-0.04 to 0.13)	21.17	0.02 (-0.02 to 0.07)	21.17
Trospium 40mg	Headache	Rudy, 2006[367]	18/329	15/329	0.02 (-0.06 to 0.10)	24.58	0.01 (-0.02 to 0.05)	24.58
Trospium 60mg	Headache	Staskin, 2007[45]	3/298	8/303	-0.06 (-0.14 to 0.02)	23.2	-0.02 (-0.03 to 0.01)	23.2
Trospium 60mg	Headache	Sand, 2009[371]	7/484	14/505	-0.05 (-0.11 to 0.02)	31.05	-0.01 (-0.02 to 0.01)	31.05
Trospium	Headache	Pooled	45/1373	49/1398	-0.02 (-0.06 to 0.03)	100	-0.01 (-0.02 to 0.01)	100
Trospium	Headache	Heterogeneity			p value 0.182	38.30%	I-squared	38.30%
Trospium 60mg	Nausea	Staskin, 2007[45]	3/298	2/303	0.02 (-0.06 to 0.10)	39.91	0.00 (-0.01 to 0.03)	39.91
Trospium 60mg	Nausea	Sand, 2009[371]	7/484	1/505	0.08 (0.01 to 0.14)	60.09	0.01 (0.00 to 0.03)	60.09
Trospium	Nausea	Pooled	10/782	3/808	0.05 (0.00 to 0.11)	100	0.01 (0.00 to 0.02)	100
Trospium	Nausea	Heterogeneity			p value 0.272	17.30%	I-squared	17.30%
Trospium 40mg	Urinary tract infection	Rudy, 2006[367]	16/329	8/329	0.07 (-0.01 to 0.14)	29.28	0.02 (0.00 to 0.06)	29.28
Trospium 60mg	Urinary tract infection	Staskin, 2007[45]	6/298	3/303	0.04 (-0.04 to 0.12)	26.74	0.01 (-0.01 to 0.04)	26.74
Trospium 60mg	Urinary tract infection	Sand, 2009[371]	7/484	4/505	0.03 (-0.03 to 0.09)	43.98	0.01 (0.00 to 0.03)	43.98
Trospium	Urinary tract infection	Pooled	29/1111	15/1137	0.05 (0.00 to 0.09)	100	0.01 (0.00 to 0.03)	100
Trospium	Urinary tract infection	Heterogeneity			p value 0.791	0.00%	I-squared	0.00%
Trospium 40mg	Abdominal pain	Zinner, 2004[35]	8/262	3/261	0.07 (-0.02 to 0.15)	24.76	0.02 (0.00 to 0.06)	24.76

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Abdominal pain	Staskin, 2007[45]	3/298	2/303	0.02 (-0.06 to 0.10)	28.45	0.00 (-0.01 to 0.03)	28.45
Trospium 60mg	Abdominal pain	Sand, 2009[371]	7/484	2/505	0.06 (-0.01 to 0.12)	46.8	0.01 (0.00 to 0.03)	46.8
Trospium	Abdominal pain	Pooled	18/1044	7/1069	0.05 (0.01 to 0.09)	100	0.01 (0.00 to 0.02)	100
Trospium	Abdominal pain	Heterogeneity			p value 0.67	0.00%	I-squared	0.00%
Trospium 40mg	Adverse effects	Rudy, 2006[367]	196/329	153/329	0.13 (0.06 to 0.21)	22.18	0.13 (0.05 to 0.20)	22.18
Trospium 40mg	Adverse effects	Junemann, 2000[316]	26/76	12/79	0.11 (0.03 to 0.19)	20.26	0.09 (0.02 to 0.16)	20.26
Trospium 60mg	Adverse effects	Staskin, 2007[45]	80/298	53/303	0.09 (0.01 to 0.18)	19.01	0.07 (0.01 to 0.15)	19.01
Trospium 60mg	Adverse effects	Dmochowski, 2008[272]	154/280	130/284	0.15 (0.08 to 0.21)	33.32	0.15 (0.08 to 0.20)	33.32
Trospium 60mg	Adverse effects	Sand, 2009[371]	138/484	83/505	0.22 (0.07 to 0.38)	5.22	0.19 (0.05 to 0.35)	5.22
Trospium	Adverse effects	Pooled	594/1467	431/1500	0.13 (0.09 to 0.17)	100	0.12 (0.09 to 0.16)	100
Trospium	Adverse effects	Heterogeneity			p value 0.627	0.00%	I-squared	0.00%
Trospium 20mg	Central nervous system disorders	Staskin, 2004[378]	19/327	17/326	0.01 (-0.06 to 0.09)	53.66	0.01 (-0.02 to 0.05)	53.66
Trospium 60mg	Central nervous system disorders	Dmochowski, 2008[272]	5/280	6/284	-0.01 (-0.09 to 0.07)	46.34	0.00 (-0.02 to 0.03)	46.34
Trospium	Central nervous system disorders	Pooled	24/607	23/610	0.00 (-0.06 to 0.06)	100	0.00 (-0.02 to 0.03)	100
Trospium	Central nervous system disorders	Heterogeneity			p value 0.664	0.00%	I-squared	0.00%
Trospium 40mg	Constipation	Zinner, 2004[35]	25/262	10/261	0.12 (0.03 to 0.20)	16.99	0.06 (0.01 to 0.11)	16.99
Trospium 40mg	Constipation	Rudy, 2006[367]	36/329	19/329	0.09 (0.02 to 0.17)	20.06	0.05 (0.01 to 0.10)	20.06

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Constipation	Staskin, 2007[45]	28/298	4/303	0.20 (0.12 to 0.28)	18.81	0.08 (0.04 to 0.13)	18.81
Trospium 60mg	Constipation	Dmochowski, 2008[272]	21/280	5/284	0.14 (0.06 to 0.23)	17.96	0.06 (0.02 to 0.11)	17.96
Trospium 60mg	Constipation	Sand, 2009[371]	43/484	6/505	0.19 (0.13 to 0.26)	26.18	0.08 (0.04 to 0.12)	26.18
Trospium	Constipation	Pooled	153/1653	44/1682	0.15 (0.11 to 0.19)	100	0.07 (0.05 to 0.09)	100
Trospium	Constipation	Heterogeneity			p value 0.221	30.10%	I-squared	30.10%
Trospium 40mg	Diarrhea	Zinner, 2004[35]	8/262	14/261	-0.06 (-0.14 to 0.03)	44.28	-0.02 (-0.05 to 0.01)	44.28
Trospium 40mg	Diarrhea	Rudy, 2006[367]	7/329	13/329	-0.05 (-0.13 to 0.02)	55.72	-0.02 (-0.03 to 0.01)	55.72
Trospium	Diarrhea	Pooled	15/591	27/590	-0.06 (-0.11 to 0.00)	100	-0.02 (-0.04 to 0.00)	100
Trospium	Diarrhea	Heterogeneity			p value 0.941	0.00%	I-squared	0.00%
Trospium 60mg	Treatment discontinuation	U.S. Food and Drug Administration[38,44]	37/280	36/284	0.01 (-0.08 to 0.09)	48.41	0.01 (-0.05 to 0.07)	48.41
Trospium 60mg	Treatment discontinuation	U.S. Food and Drug Administration[38,44]	35/298	30/303	0.03 (-0.05 to 0.11)	51.59	0.02 (-0.03 to 0.07)	51.59
Trospium	Treatment discontinuation	Pooled	72/578	66/587	0.02 (-0.04 to 0.08)	100	0.01 (-0.02 to 0.05)	100
Trospium	Treatment discontinuation	Heterogeneity			p value 0.711	0.00%	I-squared	0.00%
Trospium 40mg	Treatment discontinuation due to adverse effects	Zinner, 2004[35]	23/262	15/261	0.06 (-0.03 to 0.15)	13.29	0.03 (-0.01 to 0.09)	13.29
Trospium 40mg	Treatment discontinuation due to adverse effects	Rudy, 2006[367]	24/329	15/329	0.06 (-0.02 to 0.13)	16.72	0.03 (-0.01 to 0.07)	16.72
Trospium 60mg	Treatment discontinuation due to adverse effects	Staskin, 2007[45]	12/298	11/303	0.01 (-0.07 to 0.09)	15.27	0.00 (-0.02 to 0.04)	15.27

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Arcsine transformed absolute risk differences were poled with random effects models

Drug, daily dose	Adverse effect	Reference	Events/ randomized with drug	Events/ randomized with placebo	Arcsine transformed difference (95% CI)	Weight, random effects	Converted absolute risk difference* (95% CI)	Weight, random effects
Trospium 60mg	Treatment discontinuation due to adverse effects	Sand, 2009[371]	24/484	18/505	0.04 (-0.03 to 0.10)	25.12	0.01 (-0.01 to 0.04)	25.12
Trospium 60mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[38,44]	18/280	8/284	0.09 (0.01 to 0.17)	14.33	0.04 (0.00 to 0.08)	14.33
Trospium 60mg	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[38,44]	12/298	11/303	0.01 (-0.07 to 0.09)	15.27	0.00 (-0.02 to 0.04)	15.27
Trospium	Treatment discontinuation due to adverse effects	Pooled	113/1951	78/1985	0.04 (0.01 to 0.07)	100	0.02 (0.00 to 0.03)	100
Trospium	Treatment discontinuation due to adverse effects	Heterogeneity			p value 0.736	0.00%	I-squared	0.00%

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	9/279	10/267	0.9 (0.3; 2.1)	6.07	-0.01 (-0.04; 0.03)	8.74
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	14/314	40/781	0.7 (0.2; 2.2)	3.93	-0.05 (0.03; 6.82)	6.82
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 1981[37]	4/159	19/430	0.9 (0.5; 1.6)	11.5	-0.03 (0.02; 9.93)	9.93
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	20/400	11/406	1.3 (0.8; 2.0)	19.46	-0.01 (0.04; 11.79)	11.79
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2008[60]	15/641	4/224	0.6 (0.2; 1.7)	4.42	-0.05 (0.01; 8.62)	8.62
Solifenacin	Treatment discontinuation due to adverse effects	Karram, 2009[320]	24/372	17/367	1.6 (0.9; 2.9)	12.59	-0.01 (0.06; 8.90)	8.9
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	7/269	10/267	1.9 (0.9; 4.0)	8.57	0.00 (0.05; 10.34)	10.34
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	51/778	40/781	2.8 (1.1; 7.4)	5.46	0.01 (0.08; 7.94)	7.94
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 1981[37]	31/452	19/430	1.3 (0.4; 4.0)	4.28	-0.02 (0.03; 12.95)	12.95

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	26/385	11/406	1.4 (0.8; 2.7)	11.07	-0.02 (0.05; 8.04)	8.04
Solifenacin	Treatment discontinuation due to adverse effects	Chu, 2009[264]	37/340	18/332	2.1 (1.2; 3.8)	12.66	0.01 (0.10; 5.94)	5.94
Solifenacin	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	237/4389	198/4691	1.4 (1.1; 1.7)	100	0.00 (0.02; 100.00)	100
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001[312]	3/97	1/51	0.1 (0.0; 0.7)	5.55	-0.43 (0.03; 0.38)	0.38
Tolterodine	Treatment discontinuation due to adverse effects	Abrams, 1998[219]	10/118	7/57	0.7 (0.2; 1.8)	12.68	-0.14 (0.06; 2.00)	2
Tolterodine	Treatment discontinuation due to adverse effects	Drutz, 1999[279]	7/109	4/56	0.9 (0.3; 3.2)	9.87	-0.09 (0.07; 2.85)	2.85
Tolterodine	Treatment discontinuation due to adverse effects	Malone-Lee, 2001[346]	7/73	1/74	7.7 (0.9; 64.6)	4.68	0.01 (0.16; 3.54)	3.54
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001[312]	2/103	1/51	1.6 (0.2; 15.7)	4.13	-0.04 (0.06; 6.42)	6.42
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	5/266	10/267	1.0 (0.1; 11.2)	3.74	-0.05 (0.05; 7.53)	7.53

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Tolterodine	Treatment discontinuation due to adverse effects	Khullar, 2004[325]	26/569	16/285	0.5 (0.1; 1.7)	10.02	-0.06 (0.02; 10.89)	10.89
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2007[253]	9/290	6/285	0.8 (0.4; 1.5)	18.49	-0.04 (0.02; 12.95)	12.95
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2008[301]	12/410	2/207	1.5 (0.5; 4.2)	12.37	-0.02 (0.04; 16.35)	16.35
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	28/684	6/334	3.1 (0.7; 13.9)	7.9	0.00 (0.04; 20.02)	20.02
Tolterodine	Treatment discontinuation due to adverse effects	Rentzhog, 1998[360]	2/67	3/13	2.3 (0.7; 7.8)	10.58	0.00 (0.05; 17.08)	17.08
Tolterodine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	111/2786	57/1680	1.0 (0.6; 1.7)	100	-0.01 (0.02; 100.00)	100
Propiverine	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	26/402	11/406	5.8 (0.7; 45.4)	16.22	0.00 (0.04; 75.15)	75.15
Propiverine	Treatment discontinuation due to adverse effects	Junemann, 2006[315]	11/391	1/202	2.3 (0.9; 5.7)	83.78	0.00 (0.07; 24.85)	24.85
Propiverine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	37/793	12/608	2.7 (1.2; 6.2)	100	0.01 (0.04; 100.00)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	11/186	7/183	1.6 (0.6; 4.2)	14.64	-0.02 (0.07; 13.04)	13.04
Fesoterodine	Treatment discontinuation due to adverse effects	Dmochowski, 2010[469]	34/438	21/445	0.4 (0.1; 1.7)	8.74	-0.06 (0.01; 16.63)	16.63
Fesoterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	44/679	6/334	3.4 (1.4; 8.1)	16.74	0.03 (0.13; 10.17)	10.17
Fesoterodine	Treatment discontinuation due to adverse effects	Kaplan, 2010[318]	48/963	10/480	1.7 (1.0; 3.0)	26.8	0.00 (0.06; 17.48)	17.48
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	3/173	7/183	3.8 (1.2; 12.3)	11.01	0.02 (0.07; 19.39)	19.39
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	22/186	7/183	2.5 (1.2; 4.9)	22.07	0.01 (0.05; 23.29)	23.29
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled (IV) odds ratio and ARD with divided placebo size and rates	163/2625	59/1808	2.0 (1.3; 3.1)	100	0.01 (0.05; 100.00)	100
Fesoterodine	Continence	Kaplan, 2010[318]	609/963	258/480	1.5 (1.1; 2.0)	55.67	0.02 (0.17; 54.82)	54.82
Fesoterodine	Continence	NCT00444925[56]	396/685	138/337	2.0 (1.4; 2.8)	44.33	0.08 (0.25; 45.18)	45.18
Fesoterodine	Continence	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1005/1648	396/817	1.7 (1.3; 2.2)	100	0.06 (0.20; 100.00)	100
Tolterodine	Continence	Rogers, 2008[365]	115/202	89/211	1.8 (1.2; 2.7)	21.76	0.05 (0.24; 19.86)	19.86

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Odds ratios and absolute risk differences pooled with maximum likelihood approach (continued)

Drug	Outcome	Reference	Events/ randomized with drug	Events/ randomized with placebo	Odds ratio (95% CI)	Weight random effects	Absolute risk difference (95% CI)	Weight, random effects
Tolterodine	Continence	Malone-Lee, 2009[345]	41/165	26/142	1.5 (0.8; 2.6)	11.2	-0.03 (0.16; 21.33)	21.33
Tolterodine	Continence	Kaplan, 2010[318]	566/974	258/480	1.2 (0.9; 1.6)	39.12	-0.03 (0.11; 33.50)	33.5
Tolterodine	Continence	NCT00444925[56]	358/690	138/337	1.6 (1.1; 2.2)	27.91	0.03 (0.19; 25.32)	25.32
Tolterodine	Continence	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1080/2031	511/1170	1.4 (1.2; 1.7)	100	0.04 (0.13; 100.00)	100
Fesoterodine	Improvement in UI	Dmochowski, 2010[469]	182/438	137/445	1.6 (1.2; 2.1)	62.29	0.05 (0.17; 62.30)	62.3
Fesoterodine	Improvement in UI	Herschorn, 2010[470]	293/679	113/334	1.5 (1.0; 2.1)	37.71	0.01 (0.18; 37.70)	37.7
Fesoterodine	Improvement in UI	Pooled (IV) odds ratio and ARD with divided placebo size and rates	474/1117	250/779	1.6 (1.3; 1.9)	100	0.05 (0.15; 100.00)	100
Tolterodine	Improvement in UI	Kelleher, 2002[323]	294/507	218/508	1.8 (1.4; 2.4)	17.43	0.09 (0.21; 15.05)	15.05
Tolterodine	Improvement in UI	Herschorn, 2008[301]	156/410	64/207	1.4 (1.0; 2.0)	13.51	-0.01 (0.15; 13.37)	13.37
Tolterodine	Improvement in UI	Sand, 2009[370]	140/227	167/430	2.5 (1.8; 3.5)	14.38	0.15 (0.31; 13.41)	13.41
Tolterodine	Improvement in UI	Rogers, 2009[364]	79/202	58/211	1.7 (1.1; 2.6)	11.69	0.03 (0.21; 12.28)	12.28
Tolterodine	Improvement in UI	Herschorn, 2010[470]	256/684	113/334	1.4 (1.1; 1.7)	18.31	0.02 (0.13; 15.78)	15.78
Tolterodine	Improvement in UI	Kaplan, 2010[318]	654/974	287/480	1.2 (0.8; 1.9)	11.15	-0.02 (0.06; 16.90)	16.9
Tolterodine	Improvement in UI	NCT00444925[56]	79/690	32/337	1.2 (0.8; 1.7)	13.54	-0.05 (0.12; 13.21)	13.21
Tolterodine	Improvement in UI	Pooled (IV) odds ratio and ARD with divided placebo size and rates	1658/3694	939/2507	1.6 (1.3; 1.9)	100	0.04 (0.15; 100.00)	100

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Darifenacin	Treatment discontinuation due to adverse effects	Steers, 200543	12/108	4/41	1.1 (0.4; 3.3)	10.85	0.02 (-0.02; 0.06)	5.3
Darifenacin	Treatment discontinuation due to adverse effects	Hill, 200642	2/108	3/109	0.7 (0.1; 3.9)	5.59	0.00 (-0.03; 0.02)	17.3
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2007255	12/266	9/133	0.7 (0.3; 1.5)	22.45	0.01 (-0.02; 0.04)	11.4
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	3/229	3/164	0.7 (0.1; 3.5)	6.54	-0.01 (-0.04; 0.02)	13.4
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004472	0/53	2/164	0.6 (0.0; 12.5)	2.31	0.00 (-0.02; 0.02)	19.5
Darifenacin	Treatment discontinuation due to adverse effects	Steers, 200543	6/160	4/41	0.4 (0.1; 1.3)	11.91	0.01 (-0.04; 0.06)	1.7
Darifenacin	Treatment discontinuation due to adverse effects	Zinner, 2006407	17/214	10/225	1.8 (0.8; 3.8)	18.24	-0.01 (-0.06; 0.04)	2.2
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	8/112	4/115	2.1 (0.6; 6.6)	7.38	0.00 (-0.04; 0.03)	9.7
Darifenacin	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration41, 390	3/115	3/164	1.4 (0.3; 6.9)	4.63	0.04 (0.00; 0.08)	4.3

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Darifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004[472]	3/229	2/164	1.1 (0.2; 6.4)	4.36	0.02 (-0.01; 0.06)	8.1
Darifenacin	Treatment discontinuation due to adverse effects	Hill, 2006[42]	13/115	3/109	4.1 (1.2; 14.0)	5.76	-0.01 (-0.05; 0.03)	7
Darifenacin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	79/1709	47/1429	1.2 (0.9; 1.8)	100	0.01 (-0.01; 0.03)	100
Darifenacin	Improvement in UI	Hill, 2006[42]	28/108	15/109	1.9 (1.1; 3.3)	9.39	0.12 (0.10; 0.14)	32.5
Darifenacin	Improvement in UI	Chapple, 2007[255]	122/266	47/133	1.3 (1.0; 1.7)	39.41	0.12 (0.10; 0.14)	32.4
Darifenacin	Improvement in UI	Steers, 2005[43]	160/268	60/127	1.3 (1.0; 1.6)	51.2	0.12 (0.10; 0.14)	35.1
Darifenacin	Improvement in UI	Pooled RR (MH) and ARD (ML)	310/642	122/369	1.3 (1.1; 1.6)	100	0.12 (0.06; 0.18)	100
Fesoterodine	Continence	Kaplan, 2010[318]	609/963	258/480	1.2 (1.1; 1.3)	65.05	0.11 (0.06; 0.15)	52.9
Fesoterodine	Continence	NCT00444925[56]	396/685	138/337	1.4 (1.2; 1.6)	34.95	0.15 (0.10; 0.20)	47.1
Fesoterodine	Continence	Pooled RR (MH) and ARD (ML)	1005/1648	396/817	1.3 (1.2; 1.4)	100	0.13 (0.07; 0.19)	100
Fesoterodine	Improvement in UI	Dmochowski, 2010[469]	182/438	137/445	1.4 (1.1; 1.6)	47.29	0.10 (0.08; 0.12)	50
Fesoterodine	Improvement in UI	Herschorn, 2010[470]	293/679	113/334	1.3 (1.1; 1.5)	52.71	0.10 (0.08; 0.12)	50
Fesoterodine	Improvement in UI	Pooled RR (MH) and ARD (ML)	474/1117	250/779	1.3 (1.2; 1.5)	100	0.10 (0.05; 0.15)	100
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	11/186	7/183	1.5 (0.6; 3.9)	11.18	0.03 (-0.01; 0.06)	12.8

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued)
Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Fesoterodine	Treatment discontinuation due to adverse effects	Dmochowski, 2010[469]	34/438	21/445	1.6 (1.0; 2.8)	33	-0.01 (-0.03; 0.02)	16.3
Fesoterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	44/679	6/334	3.6 (1.6; 8.4)	12.74	0.05 (0.02; 0.09)	10
Fesoterodine	Treatment discontinuation due to adverse effects	Kaplan,[318]	48/963	10/480	2.4 (1.2; 4.7)	21.14	0.03 (0.00; 0.06)	17.2
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	3/173	7/183	0.5 (0.1; 1.7)	10.77	0.04 (0.02; 0.07)	20.9
Fesoterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[261]	22/186	7/183	3.1 (1.4; 7.1)	11.18	0.03 (0.01; 0.05)	22.9
Fesoterodine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	163/2625	59/1808	2.1 (1.5; 2.8)	100	0.03 (0.01; 0.05)	100
Oxybutynin	Improvement in UI	Moore, 1990[351]	10/28	1/25	8.9 (1.2; 64.9)	0.56	0.15 (0.02; 0.27)	9.5
Oxybutynin	Improvement in UI	Johnson, 2005[313]	4/46	1/38	3.3 (0.4; 28.3)	0.58	0.24 (0.11; 0.37)	8.4
Oxybutynin	Improvement in UI	Szonyi, 1995[382]	22/28	16/29	1.4 (1.0; 2.1)	8.26	0.09 (-0.03; 0.20)	10.5
Oxybutynin	Improvement in UI	Wang, 2006[413]	2/23	0/21	4.6 (0.2; 90.3)	0.27	0.19 (0.05; 0.33)	6.5
Oxybutynin	Improvement in UI	Homma, 20034[307]	129/244	31/122	2.1 (1.5; 2.9)	21.67	0.21 (0.09; 0.33)	10.1
Oxybutynin	Improvement in UI	Madersbacher, 1999[343]	116/145	43/72	1.3 (1.1; 1.6)	30.21	0.19 (0.09; 0.30)	12.5

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Oxybutynin	Improvement in UI	Burgio, 1998[238]	37/67	20/65	1.8 (1.2; 2.7)	10.67	0.25 (0.16; 0.34)	15.1
Oxybutynin	Improvement in UI	Thuroff, 1991[386]	26/63	15/52	1.4 (0.9; 2.4)	8.64	0.09 (0.00; 0.17)	15.4
Oxybutynin	Improvement in UI	Abrams, 1998[219]	58/118	27/57	1.0 (0.7; 1.4)	19.14	0.12 (0.01; 0.23)	12
Oxybutynin	Improvement in UI	Pooled RR (MH) and ARD (ML)	405/762	153/481	1.6 (1.4; 1.8)	100	0.17 (0.10; 0.24)	100
Oxybutynin	Treatment discontinuation due to adverse effects	Homma, 2003[307]	42/244	11/122	1.9 (1.0; 3.6)	38.62	0.04 (-0.01; 0.09)	25.5
Oxybutynin	Treatment discontinuation due to adverse effects	Staskin, 2009[31]	19/389	13/400	1.5 (0.8; 3.0)	33.76	0.06 (-0.02; 0.13)	9.6
Oxybutynin	Treatment discontinuation due to adverse effects	Thuroff, 1991[386]	2/63	0/52	4.1 (0.2; 84.4)	1.44	0.08 (0.02; 0.14)	18.8
Oxybutynin	Treatment discontinuation due to adverse effects	Abrams, 1998[219]	20/118	7/57	1.4 (0.6; 3.1)	24.86	0.10 (0.00; 0.19)	3.4
Oxybutynin	Treatment discontinuation due to adverse effects	Zinner, 2005[405]	4/19	0/19	9.0 (0.5; 156.4)	1.32	0.02 (-0.01; 0.05)	42.8
Oxybutynin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	87/833	31/650	1.8 (1.2; 2.6)	100	0.06 (0.01; 0.11)	100
Oxybutynin	Continence	Moore, 1990[351]	5/28	0/25	9.9 (0.6; 169.9)	0.67	0.15 (0.07; 0.23)	10.6
Oxybutynin	Continence	Staskin, 2009[31]	108/389	69/400	1.6 (1.2; 2.1)	86.47	0.14 (0.05; 0.24)	1.4

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Oxybutynin	Continence	Goode, 2004[291]	15/67	8/65	1.8 (0.8; 4.0)	10.32	0.13 (0.05; 0.20)	15
Oxybutynin	Continence	Lehtoranta, 2002[334]	4/9	2/9	2.0 (0.5; 8.3)	2.54	0.12 (0.07; 0.16)	73.1
Oxybutynin	Continence	Pooled RR (MH) and ARD (ML)	132/493	79/499	1.7 (1.3; 2.2)	100	0.13 (0.06; 0.21)	100
Propiverine	Improvement in UI	Lee, 2010[333]	55/176	12/88	2.3 (1.3; 4.1)	10.6	0.19 (0.15; 0.23)	52.2
Propiverine	Improvement in UI	Junemann, 2006[315]	264/391	94/202	1.5 (1.2; 1.7)	82.11	0.18 (0.14; 0.22)	36.6
Propiverine	Improvement in UI	Dorschner, 2000[278]	19/49	11/49	1.7 (0.9; 3.2)	7.29	0.18 (0.14; 0.23)	11.2
Propiverine	Improvement in UI	Pooled RR (MH) and ARD (ML)	338/616	117/339	1.6 (1.3; 1.8)	100	0.19 (0.12; 0.25)	100
Propiverine	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	26/402	11/406	2.4 (1.2; 4.8)	89.25	0.03 (0.02; 0.04)	69.5
Propiverine	Treatment discontinuation due to adverse effects	Junemann, 2006[315]	11/391	1/202	5.7 (0.7; 43.7)	10.75	0.03 (0.02; 0.05)	30.5
Propiverine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	37/793	12/608	2.7 (1.4; 5.3)	100	0.03 (0.01; 0.05)	100
Propiverine	Continence	Junemann, 2006[315]	211/391	77/202	1.4 (1.2; 1.7)	87.13	0.17 (0.14; 0.20)	84
Propiverine	Continence	Dorschner, 2000[278]	24/49	15/49	1.6 (1.0; 2.7)	12.87	0.17 (0.14; 0.20)	16
Propiverine	Continence	Pooled RR (MH) and ARD (ML)	235/440	92/251	1.4 (1.2; 1.7)	100	0.17 (0.09; 0.25)	100
Solifenacin	Improvement in UI	Toglia, 2009[321]	260/372	206/367	1.2 (1.1; 1.4)	65.43	0.15 (0.10; 0.21)	49.6
Solifenacin	Improvement in UI	Vardy, 2009[392]	196/386	109/382	1.8 (1.5; 2.1)	34.57	0.21 (0.15; 0.26)	50.4

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Solifenacin	Improvement in UI	Pooled RR (MH) and ARD (ML)	456/758	314/749	1.4 (1.3; 1.6)	100	0.18 (0.11; 0.25)	100
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	9/279	10/267	0.9 (0.4; 2.1)	5.82	0.00 (-0.02; 0.03)	8.5
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	14/314	40/781	0.9 (0.5; 1.6)	13.05	0.00 (-0.03; 0.02)	8.8
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 2006[37]	4/159	19/430	0.6 (0.2; 1.6)	5.84	0.02 (0.00; 0.04)	10
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	20/400	11/406	1.8 (0.9; 3.8)	6.21	0.03 (0.01; 0.05)	8.9
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2008[60]	15/641	4/224	1.3 (0.4; 3.9)	3.37	0.01 (-0.01; 0.03)	12.3
Solifenacin	Treatment discontinuation due to adverse effects	Karram, 2009[320]	24/372	17/367	1.4 (0.8; 2.5)	9.74	0.02 (-0.01; 0.04)	7.8
Solifenacin	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	7/269	10/267	0.7 (0.3; 1.8)	5.71	0.03 (0.00; 0.06)	5.8
Solifenacin	Treatment discontinuation due to adverse effects	Cardozo, 2006[412]	51/778	40/781	1.3 (0.9; 1.9)	22.72	0.00 (-0.02; 0.02)	9.6

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Solifenacin	Treatment discontinuation due to adverse effects	Staskin, 2006[37]	31/452	19/430	1.6 (0.9; 2.7)	11.08	0.01 (-0.01; 0.03)	11.3
Solifenacin	Treatment discontinuation due to adverse effects	Yamaguchi, 2007[403]	26/385	11/406	2.5 (1.2; 5.0)	6.09	-0.01 (-0.03; 0.02)	8.4
Solifenacin	Treatment discontinuation due to adverse effects	Chu, 2009[264]	37/340	18/332	2.0 (1.2; 3.5)	10.36	0.02 (0.00; 0.04)	8.6
Solifenacin	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	237/4389	198/4691	1.4 (1.1; 1.6)	100	0.01 (0.00; 0.03)	100
Solifenacin	Continence	Cardozo, 2006[412]	160/314	266/781	1.5 (1.3; 1.7)	18.61	0.11 (0.05; 0.16)	13.9
Solifenacin	Continence	Staskin, 1981[37]	49/159	122/430	1.1 (0.8; 1.4)	8.04	0.04 (0.00; 0.08)	16.2
Solifenacin	Continence	Karram, 2009[320]	133/372	93/367	1.4 (1.1; 1.8)	11.42	0.11 (0.05; 0.17)	13.7
Solifenacin	Continence	Vardy, 2009[392]	48/386	36/382	1.3 (0.9; 2.0)	4.41	0.15 (0.10; 0.21)	14.1
Solifenacin	Continence	Cardozo, 2006[412]	405/778	266/781	1.5 (1.4; 1.7)	32.39	0.17 (0.12; 0.21)	15.7
Solifenacin	Continence	Staskin, 2006[37]	184/452	122/430	1.4 (1.2; 1.7)	15.25	0.06 (-0.01; 0.12)	12.1
Solifenacin	Continence	Chu, 2009[264]	119/340	80/332	1.5 (1.1; 1.8)	9.88	0.12 (0.07; 0.17)	14.3
Solifenacin	Continence	Pooled RR (MH) and ARD (ML)	1098/2801	984/3503	1.4 (1.3; 1.5)	100	0.11 (0.06; 0.15)	100
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001[312]	3/97	1/51	1.6 (0.2; 14.8)	1.83	0.00 (-0.05; 0.04)	0.4

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tolterodine	Treatment discontinuation due to adverse effects	Abrams, 1998[219]	10/118	7/57	0.7 (0.3; 1.7)	13.21	0.00 (-0.05; 0.04)	2.1
Tolterodine	Treatment discontinuation due to adverse effects	Drutz, 1999[279]	7/109	4/56	0.9 (0.3; 2.9)	7.39	-0.01 (-0.04; 0.01)	14
Tolterodine	Treatment discontinuation due to adverse effects	Malone-Lee, 2001[346]	7/73	1/74	7.1 (0.9; 56.2)	1.39	0.02 (0.00; 0.04)	17.9
Tolterodine	Treatment discontinuation due to adverse effects	Jacquetin, 2001[312]	2/103	1/51	1.0 (0.1; 10.7)	1.87	0.02 (0.00; 0.04)	18.2
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2004[52]	5/266	10/267	0.5 (0.2; 1.4)	13.97	0.00 (-0.04; 0.04)	2.9
Tolterodine	Treatment discontinuation due to adverse effects	Khullar, 2004[325]	26/569	16/285	0.8 (0.4; 1.5)	29.83	0.03 (-0.01; 0.07)	3.6
Tolterodine	Treatment discontinuation due to adverse effects	Chapple, 2007[253]	9/290	6/285	1.5 (0.5; 4.1)	8.47	0.01 (-0.03; 0.04)	6.4
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2008[301]	12/410	2/207	3.0 (0.7; 13.4)	3.72	0.00 (-0.03; 0.04)	7.4
Tolterodine	Treatment discontinuation due to adverse effects	Herschorn, 2010[470]	28/684	6/334	2.3 (1.0; 5.5)	11.28	-0.01 (-0.03; 0.02)	12.2

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Tolterodine	Treatment discontinuation due to adverse effects	Rentzhog, 1998[360]	2/67	3/13	0.1 (0.0; 0.7)	7.03	0.01 (-0.01; 0.03)	15
Tolterodine	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	111/2786	57/1680	1.1 (0.8; 1.5)	100	0.01 (-0.01; 0.02)	100
Tolterodine	Continence	Rogers, 2008[365]	115/202	89/211	1.4 (1.1; 1.6)	13.47	0.06 (0.02; 0.10)	35.5
Tolterodine	Continence	Malone-Lee, 2009[345]	41/165	26/142	1.4 (0.9; 2.1)	4.33	0.10 (0.05; 0.15)	29.3
Tolterodine	Continence	Kaplan, 2010[318]	566/974	258/480	1.1 (1.0; 1.2)	53.5	0.11 (0.05; 0.17)	17.1
Tolterodine	Continence	NCT00444925[56]	358/690	138/337	1.3 (1.1; 1.5)	28.7	0.08 (0.02; 0.14)	18.1
Tolterodine	Continence	Pooled RR (MH) and ARD (ML)	1080/2031	511/1170	1.2 (1.1; 1.3)	100	0.09 (0.04; 0.14)	100
Tolterodine	Improvement in UI	Kelleher, 2002[323]	294/507	218/508	1.4 (1.2; 1.5)	20.66	0.08 (0.01; 0.15)	13.1
Tolterodine	Improvement in UI	Herschorn, 2008[301]	156/410	64/207	1.2 (1.0; 1.6)	8.07	0.11 (0.04; 0.18)	12
Tolterodine	Improvement in UI	Sand, 2009[370]	140/227	167/430	1.6 (1.4; 1.9)	10.95	0.05 (-0.01; 0.10)	14.7
Tolterodine	Improvement in UI	Rogers, 2009[364]	79/202	58/211	1.4 (1.1; 1.9)	5.38	0.08 (0.03; 0.13)	15.5
Tolterodine	Improvement in UI	Herschorn, 2010[470]	256/684	113/334	1.1 (0.9; 1.3)	14.4	0.03 (-0.01; 0.06)	16.7
Tolterodine	Improvement in UI	Kaplan, 2010[318]	654/974	287/480	1.1 (1.0; 1.2)	36.47	0.14 (0.09; 0.20)	14.8
Tolterodine	Improvement in UI	NCT0044492556	79/690	32/337	1.2 (0.8; 1.8)	4.08	0.19 (0.13; 0.26)	13.1
Tolterodine	Improvement in UI	Pooled RR (MH) and ARD (ML)	1658/3694	939/2507	1.2 (1.2; 1.3)	100	0.10 (0.05; 0.15)	100
Trospium	Continence	Zinner, 2004[35]	55/262	29/261	1.9 (1.2; 2.9)	13.14	0.11 (0.08; 0.14)	23.9

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Trospium	Continence	Staskin, 2007[45]	61/298	34/303	1.8 (1.2; 2.7)	15.24	0.11 (0.08; 0.14)	27.6
Trospium	Continence	Dmochowski, 2008[272]	95/280	58/284	1.7 (1.3; 2.2)	26.04	0.12 (0.09; 0.15)	17.6
Trospium	Continence	Sand, 2009[371]	163/484	103/505	1.7 (1.3; 2.0)	45.58	0.12 (0.09; 0.15)	30.9
Trospium	Continence	Pooled RR (MH) and ARD (ML)	374/1324	224/1353	1.7 (1.5; 2.0)	100	0.11 (0.08; 0.15)	100
Trospium	Improvement in UI	Staskin, 2004[378]	5/327	8/326	0.6 (0.2; 1.9)	5.37	0.15 (0.08; 0.23)	47.5
Trospium	Improvement in UI	Zinner, 2004[35]	186/262	141/261	1.3 (1.1; 1.5)	94.63	-0.01 (-0.03; 0.01)	52.5
Trospium	Improvement in UI	Pooled RR (MH) and ARD (ML)	191/589	149/587	1.3 (1.1; 1.5)	100	0.07 (-0.05; 0.20)	100
Trospium	Treatment discontinuation due to adverse effects	Zinner, 2004[35]	23/262	15/261	1.5 (0.8; 2.9)	19.42	0.02 (0.01; 0.04)	14.4
Trospium	Treatment discontinuation due to adverse effects	Rudy, 2006[367]	24/329	15/329	1.6 (0.9; 3.0)	19.38	0.01 (-0.01; 0.03)	18.3
Trospium	Treatment discontinuation due to adverse effects	Staskin, 2007[45]	12/298	11/303	1.1 (0.5; 2.5)	14.09	0.02 (0.00; 0.04)	8.7
Trospium	Treatment discontinuation due to adverse effects	Sand, 2009[371]	24/484	18/505	1.4 (0.8; 2.5)	22.76	0.02 (0.00; 0.04)	13.3
Trospium	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[38,44]	18/280	8/284	2.3 (1.0; 5.2)	10.26	0.01 (-0.01; 0.03)	18.3

Appendix Table F47. Clinical outcomes after drugs vs. placebo (pooled with random effects models results from RCTs) (continued) Relative risk pooled with fixed effects models, absolute risk difference pooled with maximum likelihood (continued)

Drug	Outcome	Reference	Events randomized With drug	Events randomized with placebo	Relative risk (95% CI)	Weights (M-H)	Absolute risk difference (95% CI)	Weights , maximum likelihood
Trospium	Treatment discontinuation due to adverse effects	U.S. Food and Drug Administration[38,44]	12/298	11/303	1.1 (0.5; 2.5)	14.09	0.02 (0.00; 0.03)	27.1
Trospium	Treatment discontinuation due to adverse effects	Pooled RR (MH) and ARD (ML)	113/1951	78/1985	1.5 (1.1; 1.9)	100	0.02 (0.00; 0.03)	100